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MAGNETO-MOTIVE OPTICAL DOPPLER 
TOMOGRAPHY, OPTICAL COHERENCE 
TOMOGRAPHY, AND ULTRASOUND 
MAGING METHODS AND APPARATUS 5 
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6, 2007, now U.S. Pat. No. 7,801,590, issued Sep. 21, 201, 
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60/790,248, filed Apr. 7, 2006. The aforementioned applica 




This invention was supported by funds from the National 
Institutes of Health (AR47551, EB002495 and EB002021) 
and the Texas Advanced Technology Program. The U.S. Gov- 30 
ernment may have certain rights in the invention. 
BACKGROUND 
The present invention relates in general to the art of medi- 35 
cal diagnostic imaging and in particular to imaging blood 
flow using magneto-motive optical Doppler tomography 
(MM-ODT), Optical Coherence Tomography, or Ultrasound, 
which combines an externally applied temporally oscillating 
high-strength magnetic field with ODT. OCT, or Ultrasound 40 
to detect erythrocytes moving according to the field gradient. 
The accurate determination of location and flow velocity of 
moving particles in highly scattering media, Such as blood 
flow, is important for medical diagnostics. While the mea 
surements of blood flow in the coronary arteries is an impor- 45 
tant aspect in diagnosing coronary artery diseases. Numerous 
non-invasive approaches have been developed using tech 
niques such as Doppler ultrasound, conventional angiogra 
phy, laser Doppler flowmetry and magnetic resonance 
angiography. 50 
One common sensing technique involves the use of ultra 
Sound. Using this technique, ultrasound is directed into the 
body of the patient and tiny particles such as red blood cells, 
which are Suspended in the blood plasma, scatter the ultra 
sonic energy back towards the receiver or transducer. The 55 
transducer then converts the back-scattered ultrasonic energy 
into an electrical signal that is processed in Some known 
manner to determine the presence of a flow and an estimate of 
the flow velocity. 
Magnetic resonance imaging (MRI) is based on an imaging 60 
technique for magnetically exciting nuclear spins in a subject 
positioned in a static magnetic field by applying a radio 
frequency (RF) signal of the Larmor frequency, and recon 
structing an image using MR signals induced by the excita 
tion. MRI is widely applied inclinical medicine because of its 65 
capability of clearly depicting the slightest tissue of human 
brain in vivo. 
2 
Magnetic resonance angiography (MRA) provides 
detailed angiographic images of the body in a non-invasive 
manner. In conventional MRA, which does not use contrast 
agents, magnetic resonance signal from flowing blood is opti 
mized, while signal from stationary blood or tissue structures 
is Suppressed. In contrast-enhanced MRA, a contrast agent is 
injected into the blood stream to achieve contrast between 
flowing blood and stationary tissue. 
The commonly known echo planarimaging (EPI) is a rapid 
MRI technique, which is used to produce tomographic 
images at high acquisition rates, typically several images per 
second. Functional magnetic resonance imaging (fMRI) has 
been found useful in perfusion and/or diffusion studies and in 
dynamic-contrast studies, etc. However, images obtained in 
EPI experiments tend to be vulnerable to an artifact known as 
“ghosting or 'ghost images.” 
Optical coherence tomography (OCT) is a technology that 
allows for non-invasive, cross-sectional optical imaging of 
biological media with high spatial resolution and high sensi 
tivity. OCT is an extension of low-coherence or white-light 
interferometry, in which a low temporal coherence light 
source is utilized to obtain precise localization of reflections 
internal to a probed structure along an optic axis. This tech 
nique is extended to enable scanning of the probe beam in the 
direction perpendicular to the optic axis, building up a two 
dimensional reflectivity data set, used to create a cross-sec 
tional gray-scale or false-color image of internal tissue back 
Scatter. 
OCT uses the short temporal coherence properties of 
broadband light to extract structural information from hetero 
geneous samples Such as biologic tissue. OCT has been 
applied to imaging of biological tissue in vitro and in vivo. 
Systems and methods for Substantially increasing the resolu 
tion of OCT and for increasing the information content of 
OCT images through coherent signal processing of the OCT 
interferogram data have been developed to provide cellular 
resolution (i.e., in the order of 5 micrometers). During the past 
decade, numerous advancements in OCT have been reported 
including real-time imaging speeds. 
In diagnostic procedures utilizing OCT, it would also be 
desirable to monitor the flow of blood and/or other fluids, for 
example, to detect peripheral blood perfusion, to measure 
patency in Small vessels, and to evaluate tissue necrosis. 
Another significant application would be in retinal perfusion 
analysis. Accordingly, it would be advantageous to combine 
Doppler flow monitoring with the above micron-scale reso 
lution OCT imaging in tissue. 
Conventional OCT imaging primarily utilizes a single 
backscattering feature to display intensity images. Functional 
OCT techniques process the backscattered light to provide 
additional information on birefringence, and flow properties. 
(See for example, Kemp NJ, Park J, Zaatar HN, Rylander H 
G. Milner T. E. High-sensitivity determination of birefrin 
gence in turbid media with enhanced polarization-sensitive 
optical coherence tomography, Journal of the Optical Society 
of America A: Optics Image Science and Vision 2005, 22(3): 
552-560; Dave DP, Akkin T. Milner TE, Polarization-main 
taining fiber-based optical low-coherence reflectometer for 
characterization and ranging of birefringence, Optics Letters 
2003, 28(19): 1775-1777: Rylander CG, Dave DP, Akkin T, 
Milner TE, Diller KR, Welch M. Quantitative phase-contrast 
imaging of cells with phase-sensitive optical coherence 
microscopy, Optics Letters 2004, 29(13):1509-1511; de Boer 
J. F. Milner T E, Ducros M G, Srinivas S M, Nelson J S. 
Polarization-sensitive optical coherence tomography, Hand 
book of Optical Coherence Tomography, New York: Marcel 
Dekker, Inc., 2002, pp. 237-274.) 
US 9, 198,596 B2 
3 
Since the ability to characterize fluid flow velocity using 
OCT was demonstrated by Wang et al., several phase 
resolved, real-time optical Doppler tomography (ODT) 
approaches have been reported. (See for example, Chen Z. P. 
Milner T. E. Dave D, Nelson J S. Optical Doppler tomo 
graphic imaging of fluid flow velocity in highly scattering 
media, Optics Letters 1997, 22(1):64-66: Wang XJ, Milner T 
E, Nelson J S. 
Optical Doppler tomography (ODT) combines Doppler 
velocimetry with optical coherence tomography (OCT) for 
noninvasive location and measurement of particle flow veloc 
ity in highly scattering media with micrometer-scale spatial 
resolution. The principle employed in ODT is very similar to 
that used in radar, Sonar and medical ultrasound. ODT uses a 
low coherence or broadband light source and optical interfer 
ometer to obtain high spatial resolution gating with a high 
speed scanning device Such as a conventional rapid scanning 
optical delay line (RSOD) to perform fast ranging of micro 
structure and particle motion detection in biological tissues or 
other turbid media. 
To detect the Doppler frequency shift signal induced by the 
moving particles, several algorithms and hardware schemes 
have been developed for ODT. The most straightforward 
method to determine the frequency shift involves the use of a 
short time fast Fourier transform (STFFT). However, the 
sensitivity of this method is mainly dependent on the FFT 
time window, which limits axial scanning speed and spatial 
resolution when measuring slowly moving blood flow in 
small vessels that requires high velocity sensitivity. However, 
a phase-resolved technique can decouple the Doppler sensi 
tivity and spatial resolution while maintaining high axial 
Scanning speed. 
In ODT, the Doppler frequency shift is proportional to the 
cosine of the angle between output and input Scattering direc 
tions of the probe beam and the scatterer's flow direction. 
When the two directions are perpendicular, the Doppler shift 
is Zero. Because a priori knowledge of the Doppler angle is 
not available, and conventional intensity OCT imaging pro 
vides a low contrast image of microvasculature structure, 
detecting small vessels with slow flow rates is difficult. How 
ever, the Doppler angle can be estimated by combining Dop 
pler shift and Doppler bandwidth measurements. (See for 
example, Piao DQ, Zhu Q, Quantifying Doppler Angle and 
Mapping Flow Velocity by a Combination of Doppler-shift 
and Doppler-bandwidth Measurements in Optical Doppler 
Tomography, Applied Optics, 2003, 42(25): 5158-5166, and 
U.S. Pat. No. 5,991,697 describe a method and apparatus for 
Optical Doppler Tomographic imaging of a fluid flow in a 
highly scattering medium comprising the steps of scanning a 
fluid flow sample with an optical source of at least partially 
coherent radiation through an interferometer, which is incor 
porated herein by reference). 
The ability to locate precisely the microvasculature is 
important for diagnostics and treatments requiring character 
ization of blood flow. Recently, several efforts to increase 
blood flow contrast mechanisms have been reported includ 
ing protein microspheres incorporating nanoparticles into 
their shells, plasmon-resonant gold nanoshells, and use of 
magnetically Susceptible micrometer sized particles with an 
externally applied magnetic field. (See for example, Lee TM, 
Oldenburg AL, Sitafalwalla S, Marks DL, Luo W. Toublan F 
JJ, Suslick KS, Boppart SA, Engineered microsphere con 
trast agents for optical coherence tomography, Optics Letters, 
2003, 28(17): 1546-1548; Loo C, Lin A, Hirsch L. Lee MH, 
Barton J. Halas N, West J. Drezek R. Nanoshell-enabled 
photonics-based imaging and therapy of cancer. Technology 













Oldenburg AL, Gunther JR, Boppart SA, Imaging magneti 
cally labeled cells with magnetomotive optical coherence 
tomography, Optics Letters, 2005, 30(7): 747-749.) 
Wang, et al., “Characterization of Fluid Flow Velocity by 
Optical Doppler Tomography. Optics Letters, Vol. 20, No. 
11, Jun. 1, 1995, describes an Optical Doppler Tomography 
system and method which uses optical low coherence reflec 
trometry in combination with the Doppler effect to measure 
axial profiles of fluid flow velocity in a sample. A disadvan 
tage of the Wang system is that it does not provide a method 
to determine direction of flow within the sample and also does 
not provide a method for generating a two-dimensional color 
image of the sample indicating the flow velocity and direc 
tions within the image. 
The use of an externally applied field to move magnetically 
Susceptible particles in tissue has been termed magneto-mo 
tive OCT (MM-OCT). Functional magnetic resonance imag 
ing (fMRI) detects deoxyhemoglobin which is a paramag 
netic molecule. However, the paramagnetic Susceptibility of 
human tissue is very low compared to other biocompatible 
agents such as ferumoxides (nanometer sized iron oxide par 
ticles). Therefore, it was believed that, other than differenti 
ating relaxation times (T2) between oxygenated and deoxy 
genated blood, the magnetic field strength required to 
produce a retarding force on blood flow was well above that of 
current imaging fields. (See also, for example, Schenck J. F., 
Physical interactions of static magnetic fields with living 
tissues, Progress in Biophysics and Molecular Biology 2005, 
87(2-3):185-204; and Taylor DS, Coryell, C. D., Magnetic 
susceptibility of iron in hemoglobin.J. Am. Chem. Soc. 1938, 
60.1177-1181.) 
SUMMARY OF THE INVENTION 
The invention is a method and apparatus of imaging a blood 
flow, hemoglobin, and/or nanoparticles using optical coher 
ence tomography, which comprises an externally applied 
temporally oscillating high-strength magnetic field with an 
optical tomography system to detect hemoglobin and/or 
nanoparticles. 
Another embodiment is an apparatus for imaging blood 
flow and/or nanoparticles, comprising a magnetomotive opti 
cal Doppler tomography (MM-ODT) imaging system 
Another aspect of the invention is a method for imaging a 
blood flow, comprising applying a magnetic field to the blood 
flow, wherein the blood flow comprising a plurality of hemo 
globin molecules and/or nanoparticles and wherein the mag 
netic field interacts with the hemoglobin molecules to cause a 
change in the blood flow; and detecting the blood flow by 
detecting the change in the blood flow caused by the interac 
tion with the hemoglobin molecules, wherein the change is 
detected using a magnetomotive optical Doppler tomography 
imaging System. 
In another embodiment, the invention comprises a Solenoid 
cone-shaped ferrite core with an extensively increased mag 
netic field strength at the tip of the core. In a further embodi 
ment, the invention comprises focusing the magnetic force on 
targeted samples. 
Another embodiment of the method for imaging a blood 
flow comprises temporally oscillating the magnetic field. 
Another embodiment of the invention is an apparatus for 
imaging a blood flow comprising a magnetic field generator 
for applying a magnetic field to the blood flow, wherein the 
blood flow comprises hemoglobin molecules and/or nanopar 
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ticles; and an ultrasound detection system for detecting the 
blood flow while it is in the presence of the magnetic field. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings, which are incorporated in 
and constitute a part of this specification, illustrate aspects of 
the methods, apparatuses, and systems and together with the 
description, serve to explain the principles of the methods, 
apparatuses, and systems. 
FIG. 1 is a schematic diagram of the MM-ODT system. 
FIG. 2 is a schematic diagram of the probe beam, flow 
sample and Solenoid coil. 
FIGS. 3A and 3B are OCT and ODT images of a stationary 
turbid solution without an external magnetic field, respec 
tively. FIG. 3C and FIG. 3D are OCT and ODT images with 
a 50 Hz magnetic field, respectively. The white bar represents 
200 um, accordingly. 
FIGS. 4A-4D are M-mode ODT images of the diluted 
deoxygenated blood flow (18%hematocrit) without and with 
an external magnetic field. FIG. 4A and FIG. 4B are ODT 
images of 5 mm/s blood flow without and with a 5 Hz mag 
netic field, respectively. FIG. 4C and FIG. 4D are ODT 
images of 30 mm/s blood flow without and with a 50 Hz 
magnetic field, respectively. The Black bar indicates 200 um, 
accordingly. 
FIG. 5A and FIG. 5B are the Doppler frequency shift 
profiles without an external magnetic field, and with a 50 Hz 
magnetic field, respectively. 
FIG. 6 is a block diagram illustrating an exemplary phase 
sensitive OCT system. 
FIG. 7 is a graph of the optical path length change in the 
DP-OCT system. 
FIG. 8 is a schematic diagram of Magneto Motive Ultra 
sound for Blood. 
FIG. 9 is an ultrasound image of blood exposed to an 
oscillating magnetic field. 
FIG. 10 is a schematic diagram of Ultrasonography and 
OCT coupled with magnetic field generator. 
FIGS. 11A and 11B show solenoid drive signal and optical 
pathlength change observed in a mouse imaged with metallic 
nanoparticles (11A) and a mouse imaged without metallic 
nanoparticles (11B). 
FIGS. 12A-B shows a schematic diagram of a differential 
phase optical coherence tomography (DP-OCT) system com 
bined with a magnetic field generator: (12A) DP-OCT sys 
tem, (12B) collinear configurations of the DP-OCT sample 
path and design of the magnetic field generator containing a 
conical iron core. 
FIG. 13 A-13D shows the optical path length change (Ap) 
in livers with different SPIO doses (1.0, 0.1 mmol Fe/kg and 
saline control) using focused magnetic field excitation (2 Hz, 
4V) (13A). Optical path length change (Ap) in specimens 
with doses 1.0 mmol Fe/kg SPIO (13D), 0.1 mmol Fe/kg 
SPIO (13B), and a saline control liver (13C). The applied 
magnetic flux density strength is B-0.47 Tesla at the liver 
specimen. 
FIG. 14A-B shows the maximum optical path length 
change (Ap) in iron-laden liver specimens due to nanoparticle 
movement in response to a focused magnetic field for mice 
injected with various SPIO doses (1.0 and 0.1 mmol Fe/kg). 
The input frequency is 2 HZ with applied Voltage ranging 
from 2 to 8 V (14A) and magnetic field strength at each 
input voltage (14B). 
FIG. 15A-D shows the Optical path length change (Ap) in 
iron-laden liver specimens due to nanoparticle movement in 














(1~10 Hz) input for mice injected with various SPIO doses 
(1.0 and 0.1 mmol Fe?kg). (15A). Optical path length change 
(Ap) at 1.0 mmol Fe/kg SPIOdose (15B), 0.1 mmol Fe/kg 
SPIO dose (15C), and a saline control liver (15D). The 
applied focused magnetic flux density is 1.3 Tesla at the 
specimen. 
FIGS. 16A-B shows the maximum optical path length 
change (Ap) in iron-laden liver specimens due to nanoparticle 
movement in response to a focused magnetic field with a 
swept frequency (1-10 Hz) input for mice injected with vari 
ous SPIO doses (1.0 and 0.1 mmol Fe/kg). Input swept fre 
quency ranged from 1-10 HZ over 2 seconds with input 
voltages increasing from 2 to 10 V (16A) and magnetic field 
strength at each input voltage (16B). 
FIGS. 17A-17E shows optical path length change (Ap) in 
iron-laden rabbit arteries (0.1 Fe/kg) measured in response to 
2 Hz frequency sinusoidal inputs. 
FIG. 18 is a block diagram illustrating a multi-channel 
phase sensitive OCT system. 
DETAILED DESCRIPTION OF THE INVENTION 
The methods, apparatuses, and systems can be understood 
more readily by reference to the following detailed descrip 
tion of the methods, apparatuses, and systems and the 
Examples included therein and to the Figures and their pre 
vious and following description. 
Before the present compounds, compositions, articles, 
devices, and/or methods are disclosed and described, it is to 
be understood that these are not limited to specific synthetic 
methods, specific components, or to particular compositions, 
as such may, of course, vary. It is also to be understood that the 
terminology used herein is for the purpose of describing 
particular embodiments only and is not intended to be limit 
ing. 
As used in the specification and the appended claims, the 
singular forms “a,” “an and “the include plural referents 
unless the context clearly dictates otherwise. Thus, for 
example, reference to “a nanoparticle' includes mixtures of 
nanoparticles, reference to “a nanoparticle' includes mix 
tures of two or more such nanoparticles, and the like. 
Ranges may be expressed herein as from “about one par 
ticular value, and/or to “about another particular value. 
When such a range is expressed, another embodiment 
includes from the one particular value and/or to the other 
particular value. Similarly, when values are expressed as 
approximations, by use of the antecedent “about, it will be 
understood that the particular value forms another embodi 
ment. It will be further understood that the endpoints of each 
of the ranges are significant both in relation to the other 
endpoint, and independently of the other endpoint. 
“Optional' or “optionally’ means that the subsequently 
described event or circumstance may or may not occur, and 
that the description includes instances where said event or 
circumstance occurs and instances where it does not. For 
example, the phrase “optionally substituted shelled metals' 
means that shelled metals may or may not be substituted and 
that the description includes both unsubstituted shelled met 
als and shelled metals where there is substitution. 
As used throughout, by a 'subject' is meant an individual. 
Thus, the “Subject' can include domesticated animals, such 
as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, 
goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, 
guinea pig, etc.) and birds. In one aspect, the Subject is a 
mammal such as a primate or a human, alternatively, cats, 
dogs, and other livestock may be used for testing purposes. 
The term does not denote a particular age or sex. Thus, adult 
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and newborn Subjects, as well as fetuses, whether male or 
female, are intended to be covered. 
It is to be understood that nanoparticle and/or hemoglobin 
may be affected by an external oscillating magnetic field for 
magneto-motive Optical Coherence Tomographic imaging. 
Reference will now be made in detail to exemplary aspects 
of the systems, methods, apparatuses, and/or compositions, 
examples of which are illustrated in the accompanying draw 
1ngS. 
Provided herein are methods, compositions and appara 
tuses for Magneto-Motive Optical Doppler Tomography 
(“MM-ODT”) for improved Doppler imaging of blood flow 
and/or nanoparticles using an external oscillating magnetic 
field is described below. By introducing mechanical move 
ment of red blood cells (RBCs) or nanoparticles by a tem 
porally oscillating high-strength magnetic field, MM-ODT 
allows imaging of blood flow and velocity. The controlled and 
increased Doppler frequency in MM-ODT provides an inves 
tigational tool to study in Vivo blood transport, as shown in the 
article Hemoglobin Contrast in Magnetomotive Optical Dop 
pler Tomography, Opt. Lett. 31,778-780 (2006), herein incor 
porated by reference. 
The microstructure of the blood flow and flow velocity 
information are all encoded in the interferogram of a Doppler 
OCT system. It should be readily apparent to those skilled in 
the optical arts, that different OCT systems and different OCT 
information can be used to determine the Doppler frequency 
shift. It is not intended to suggest any limitation as to the 
scope or functionality with different OCT architectures or 
optical information used with an oscillating magnetic field, 
such as time domain Doppler OCT and spectral domain Dop 
pler OCT. Time domain OCT requires a mechanism that 
varies the pathlength of light propagating in the reference 
path of the interferometer, while spectral domain OCT 
includes swept source OCT and Fourier domain OCT. An 
example of time-domain Doppler OCT is provided below. 
A schematic of the MM-ODT apparatus 10 is shown in 
FIG.1. The OCT light source 12 comprises a super lumines 
cent diode, which is used as the low coherence light source, in 
one embodiment of the invention, where the light source 12 is 
centered at 1.3 um with a bandwidth of 90 nm. Alternatively, 
a tunable laser Source in the spectral domain may be used as 
the light source 12. Light from Source 12 is coupled into a 
single-mode optical fiber based interferometer 20 by circula 
tor 14, where the interferometer 20 can provide 1 mW of 
optical power at the sample 60. Light is split into a reference 
arm 22 and sample arm 24 by a 2x2 splitter 16. A rapid 
scanning optical delay (RSOD) line 26 is coupled to the 
reference arm 22. In one embodiment, the rapid-scanning 
optical delay line 26 is aligned such that no phase modulation 
is generated when the group phase delay is scanned at ~4 kHz. 
In the sample arm 24, a collimated beam 36 is redirected to 
sample 60 by two galvanometers 30 that permit three-dimen 
sional scanning. In one embodiment, the galvanometers can 
be an X-scanner and a Y-scanner. The sample 60 can be 
internal or external to the body, where the probe beam is 
focused by an objective lens 32. In one embodiment, the 
objective lens 32 yields a 10-um spot at the focal point. Phase 
modulation can be generated using an electro-optical 
waveguide phase modulator, which can produce a carrier 
frequency (~1 MHz). And the magnetic field generator 62 is 
in proximity to the sample 60. 
A dual-balanced photodetector 34 is coupled to the 2x2 
splitter 16 and the circulator 14. The photodetector 34 of an 80 
MHz bandwidth reduces the light source noise from the OCT 
interference signal. A hardware in-phase and quadrature 














pass filters 44 improves imaging speed. Doppler information 
was calculated with the Kasai autocorrelation velocity esti 
mator. Labview software 50 (National Instruments, Austin, 
Tex.) is coupled to the MM-ODT system with a dual proces 
Sor based multitasking scheme. The maximum frame rate of 
the MM-ODT system 10 was 16 frames per second for a 
400x512 pixel sized image. The Doppler frequency shift can 
be determined with the use of a short time fast Fourier trans 
form (STFFT). Alternatively, a phase-resolved technique can 
determine the Doppler frequency shift to decouple the Dop 
pler sensitivity and spatial resolution while maintaining high 
axial scanning speed. Alternatively, differential phase optical 
coherence tomography (OCT) or spectral domain phase-sen 
sitive OCT can be used to determine the Doppler frequency 
shift, as readily determined by one skilled in the optical arts. 
FIG.2 shows an example of the magnetic field generator 80 
with a capillary tube 90. The magnetic field generator 80 
includes a solenoid coil 82 (Ledex 4EF) with a cone-shaped 
ferrite core 84 at the center and driven by a current amplifier 
86 supplying up to 960 W of power. The magnetic field 
generator 80 can be placed underneath the sample 60 during 
MM-ODT imaging. The combination of the ferrite core 84 
and Solenoid coil 82 using a high power operation dramati 
cally increases the magnetic field strength (B, 0.14 Tesla) 
at the tip of the core 82 and also focuses the magnetic force on 
the targeted samples 60. The sinusoidal current can vary the 
magnetic force applied to the capillary tube 90 in order to 
introduce movement of magnetic fluids, which include red 
blood cells that contain hemoglobin. In one embodiment, the 
probe beam is oriented parallel to the gradient of the magnetic 
field's strength. 
The material parameter characterizing magnetic materials, 
including biological tissue, is the magnetic Volume suscepti 
bility, X. Magnetic Volume Susceptibility is dimensionless in 
SI units and is defined by the equation M-H, where M is the 
magnetization at the point in question and H is the local 
density of the magnetic field strength. Hemoglobin's high 
iron content, due to four Fe atoms in each hemoglobin mol 
ecule, and the large concentration of hemoglobin in human 
red blood cells allow Hemoglobin magneto-motive effects in 
biological tissue. The magnetic Volume Susceptibility of the 
hemoglobin molecule consists of a paramagnetic component 
due to the electron spins of the four iron atoms. The paramag 
netic susceptibility is given by the Curie Law, 
HoNp (in ui) (1) 
where L is permeability of free space and has the value 
4tx107H/m, N is the Volume density of paramagnetic iron 
atoms in hemoglobin, N=4.97x10° ironatoms/m, is the 
effective number of Bohr magnetons per atom reported as 
5.35, and the Bohr magneton, L-9.274x10''J/T, and Bolt 
Zmann's constant, k=1.38x10 J/K, and T is the absolute 
temperature (K). The calculated susceptibility of a RBC is 
about 11x10 assuming a 90% concentration of hemoglobin 
per RBC. The calculated susceptibility of a RBC is dependent 
on the oxygenation of the hemoglobin. The calculations can 
be adjusted accordingly, depending on the oxygenation of the 
RBC, which can be measured by known techniques. 
A RBC placed in a magnetic field gradient experiences 
forces and torques that tend to position and align it with 
respect to the field's direction. The magnetic force, in the 
direction of the probing light Z, is given by 
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s: - . . . 
where V is the particle Volume, B is the magnitude of the 
magnetic flux density, and AX is the difference between the 
Susceptibility of the particle and the Surrounding medium. 
The displacement Z(t) of an RBC driven by a time varying 
magnetic flux density can be included in the analytic OCT 
fringe expression, Ia 
(3) 
Ao 
where I and Is are the back scattered intensities from the 
reference and sample arms, respectively, f is the fringe car 
rier frequency, X is the center wavelength of the light source, 
and Z(t) is the RBC displacement. Integration of all forces 
(magnetic, elastic, and Viscous) on the RBC gives a steady 
state displacement, Z(t) Acos(4tfit) where A is a constant in 
units of length and f is the modulation frequency of the 
magnetic flux density. In free space, the displacement, Z(t), is 
dominated a constant acceleration which can be, however, 
ignored in confined models (i.e. blood vessel or capillary 
tube) with assumptions that, first, the probing area is much 
Smaller than magnetic field area, and that secondly probing 
time starts after steady states of inner pressures. Expansion of 
the right-hand side of Eq. (3) using Bessel functions gives 
If a 2v IRI, (4) 
exp(i27tfit 
where J(m) is the Bessel function of the first kind of order K. 
for argument m which is 4. LA/. The amplitude of the k" 
sideband is proportional to J. (m). In coherent detection, the 
fraction of optical power transferred into each of the first 
order sidebands is (J (m)), and the fraction of optical power 
that remains in the carrier is (J.(m)). 
EXAMPLES 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how the compositions, compositions, articles, 
devices, systems, and/or methods claimed herein are made 
and evaluated, and are intended to be purely exemplary and 
are not intended to limit the scope of compositions, compo 
sitions, articles, devices, systems, and/or methods. Efforts 
have been made to ensure accuracy with respect to numbers 
(e.g., amounts, temperature, etc.), but some errors and devia 
tions should be accounted for. Unless indicated otherwise, 
parts are parts by weight, temperature is in degrees Celsius or 
is at ambient temperature, and pressure is at or near atmo 
spheric. 
Example 1 
MM-ODT Imaging of the Doppler Shift of 
Hemoglobin by Applying an Oscillating Magnetic 
Field to a Moving Blood Sample 
M-mode OCT/ODT images of a capillary glass tube filled 













magnetic field as a control sample were recorded, as shown in 
FIGS. 3-4. A 750 um-inner diameterglass capillary tube 200 
was placed perpendicularly to the probing beam 70, as shown 
in FIG. 2. Fluids used for flow studies were injected through 
the tube at a constant flow rate controlled by a dual-syringe 
pump (Harvard Apparatus 11 Plus, Holliston, Mass.) with 
+0.5% flow rate accuracy. The turbid solution was a mixture 
of deionized water and 0.5-gm latex microspheres (15 
mm). The magnetic flux density and its frequency were 
approximately 0.14T and 50 Hz, respectively. M-mode OCT/ 
ODT images were acquired for 100 ms per frame. FIGS. 3a 
and 3b show M-mode OCT and ODT images without any 
external magnetic field, respectively. The ODT image in FIG. 
3b contains Small random phase fluctuations due to ambient 
vibration through the optical path. FIGS. 3c and 3d show 
M-mode OCT and ODT images with a 50 Hz external mag 
netic field, respectively. No distinguishable Doppler shift 
could be observed in the ODT image FIG. 3d indicating no 
interaction between the external magnetic field and the mov 
ing microspheres. 
Deoxygenated blood was extracted from the vein of a 
human male’s left arm, and diluted with Saline. During prepa 
ration, blood was not exposed directly to air so as to remain 
deoxygenated. To simulate flow, blood was injected through 
the capillary tube 200 by a syringe pump at a relatively 
constant flow rate. As FIG. 4 shows, the oscillating Doppler 
frequency shift, resulting from RBC movement, could be 
observed at two different flow rates (5 and 30 mm/s). Because 
the flow direction was nearly perpendicular to the probing 
beam no significant Doppler frequency shift was distinguish 
able at the 5 mm/s flow rate FIG. 4a without any external 
magnetic field. In the case of the high blood flow rate of 30 
mm/s, as shown at FIG. 4c, the Doppler frequency shift 
caused by the blood flow could be observed. And for maxi 
mum contrast enhancement, the probe beam can be directed 
parallel to the gradient of the magnetic field's strength. How 
ever, application of a 50 Hz magnetic field increased the 
Doppler contrast of blood at both the slow and fast flow rates 
as shown at FIGS. 4b and 4d. The high flow rate of 30 mm/s 
gives a higher contrast image than the low flow rate image, but 
the Doppler frequency shift of the former as a function of 
depth is less homogeneous than the latter, which is indicative 
of perturbation by blood flow. The same blood was diluted to 
5 hematocrit (HCT), but no RBC movement could be 
observed below 8% HCT. 
Doppler frequency shift profiles were calculated from the 
ODT images by averaging 20 lines at a selected depth indi 
cated by horizontal arrows, as shown in FIGS. 4a and 4b. FIG. 
5a indicates no significant Doppler frequency shift over a 100 
ms time period, whereas FIG. 5b displays +200 to 300 Hz 
Doppler frequency shifts oscillating 20 times over 100 ms 
(200 Hz). 
The Doppler frequency shift indicates that RBC's physi 
cally move into and away from the incident light while pass 
ing through the external magnetic field depending on whether 
their magnetic properties are paramagnetic or diamagnetic, as 
shown in FIG. 4, and that the 200 Hz oscillation of the Dop 
pler frequency shift correlates with the 50 Hz, magnetic field, 
as shown in FIG.5. Frequencies 4 times higher than that of the 
external magnetic field (f) can be observed. According to 
Eq. 2, the frequency of the force on paramagnetic targets was 
twice that of the magnetic flux density; therefore, a 50 Hz, B 
field displaces the targets at 100 Hz. Although the fringe 
signal (Eq. 4) contains harmonics at frequency (2f ), the 
modulation frequency, f, was set so that the second-order 
sideband (4f) was dominant as shown in FIG. 5b. The par 
ticle motion can not be described as a pure sinusoidal function 
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even if the modulated magnetic field is sinusoidal, due to the 
numerous forces that contribute to the motion within the field 
Such as gravity, concentration gradient, and colloidal disper 
S1O. 
The invention is a new investigational tool to study in vivo 
blood transport and the first implementation of MM-ODT for 
improved Doppler imaging of blood flow using an external 
oscillating magnetic field introducing a mechanical move 
ment of RBCs during blood flow by a temporally oscillating 
high-strength magnetic field. MM-ODT to allow imaging of 
tissue function in a manner similar to functional magnetic 
resonance images (f-MRI) of deoxygenated blood in organs, 
when the sample arm of the MM-ODT system is coupled to a 
probe (not shown). Such probes are generally known in the 
arts, such as endoscopic probes, catheter probes, and the like. 
Alternatively, the MM-ODT can be used for Port-Wine 
vessel mapping and Skin Cancer vessel mapping. The MM 
ODT can be used to detect blood vessel location and size for 
cancer and port-wine stains, since these conditions are char 
acterized by blood vessel growth and increases in hemoglobin 
content. Accordingly, other blood vessel detection for tissue 
abnormality identification can be envisioned with this inven 
tion. Generally, the MM-ODT can be used wherever blood 
flow detection is necessary in operations, chemotherapy, 
hemodialysis, and the like. 
A spectral domain phase sensitive OCT system 100 can be 
used to image the blood flow and determine velocity infor 
mation, when an oscillating magnetic field is applied to the 
blood flow, as shown in FIG. 6. Spectral domain phase sen 
sitive OCT generally uses a broadband light source (in a 
general interferometric setup, where the mirror in the refer 
ence typically does not move or does not require a rapid 
scanning delay line. A spectral interferogram is detected, in 
which each A-scan is entirely encoded. A Fourier transfor 
mation of the A-scan and velocity distribution of the blood 
flow can be extracted by known methods. Spectral domain 
OCT can be generally understood under U.S. Pat. No. 5,991, 
697, which describes how to measure the Doppler shift. In 
spectral domain Doppler OCT, the blood flow profile is the 
envelope of a calculated A-scan through Fourier transforma 
tion on the spectral interferogram. Velocity information is 
encoded in the rate of phase change of the interferogram. The 
Doppler Velocity can be extracted by measuring the phase 
shift between two successive calculated A-scans in spectral 
domain Doppler OCT and the time between recording suc 
cessive A-scans 
This OCT system 100 is only an example of one OCT 
imaging modality which can be used to image blood flow with 
a temporally oscillating magnetic field, and is not intended to 
Suggest any limitation on the scope of OCT architectures 
applicable to the invention. Generally, the OCT system 100 
includes a general-purpose computing device in the form of a 
computer 101 and includes a magnet control 114 and a mag 
net 116. 
Light energy is generated by a light source 117. The light 
source 117 can be abroadband laser light source coupled into 
optical fiber emitting light energy over a broad range of opti 
cal frequencies. The wavelength range can be from about 400 
nanometers to about 1600 nanometers. Longer wavelengths 
(>800 nm) can be used for deeper scanning. Preferably, the 
light source emits light having a wavelength near the infrared 
spectrum to identify hemoglobin for OCT imaging, and the 
magnet 116 places hemoglobin in motion and increases opti 
cal scattering of the hemoglobin. The light energy can be 
emitted over a multiplicity of optical wavelengths, frequen 
cies, and pulse durations to achieve OCT imaging. As used 













Optical fiber is indicated on FIG. 6 as lines connecting the 
various blocks of the figures. Where light energy is described 
as “passing,” “traveling.” “returning.” “directed,” or similar 
movement, Such movement can be via optical fiber. 
A fraction of the generated light energy passes from the 
light source 117 into an optical spectrum analyzer 118. The 
optical spectrum analyzer 118 measures optical frequency as 
the light energy is emitted from the light source 117 as a 
function of time. The optical spectrum analyzer 118 samples 
a portion of the light emitted by the light source 117. The 
optical spectrum analyzer 118 monitors the power spectral 
density of light entering the splitter 119. The remaining frac 
tion of light energy from the light source 117 passes into a 
splitter 119. The splitter 119 can be a device with four ports, 
with Port 1 allowing light energy to enter the splitter 119. 
Ports 2 and 3 allow light energy to leave and re-enter the 
splitter 119 to the reference reflector 120 and OCT probe 122, 
respectively. Port 4 allows light energy to leave the splitter 
119 to coupling lens 124. The splitter 119 couples the light 
into Port 1. The splitter 119 divides the light according to a 
pre-determined split ratio selected by a user. For example, the 
split ratio can be 50/50 wherein half of the light energy 
entering the splitter 119 at Port 1 exits the splitter 119 through 
Port 2 and half exits the splitter 119 through Port 3. In another 
example, the split ratio can be 60/40 wherein 60% of the light 
energy passes through Port 2 and 40% of the light energy 
passes through Port 3. 
A fraction of the light energy (determined by the split ratio) 
that exits the splitter 119 through Port 2 travels to a reference 
reflector surface 120. The light energy is reflected from the 
reference reflector surface 120 back to the splitter 119 into 
Port 2. The reference reflector 120 can be a planar metallic 
mirror or a multilayer dielectric reflector with a specified 
spectral amplitude/phase reflectivity. The remaining fraction 
of light that entered splitter 119 through Port 1 exits splitter 
119 through Port 3 and enters an OCT probe 122. The OCT 
probe 122 can be a turbine-type catheter as described in 
Patent Cooperation Treaty application PCT/US04/12773 
filed Apr. 23, 2004 which claims priority to U.S. provisional 
application 60/466.215 filed Apr. 28, 2003, each herein incor 
porated by reference for the methods, apparatuses and sys 
tems taught therein. The OCT probe 122 can be located within 
a subject 121 to allow light reflection off of subject's 121 
blood flow. 
The light energy that entered OCT probe 122 is reflected 
off of the blood flow of subject 121 once an oscillating mag 
netic field has been temporally applied by magnet 116. The 
reflected light energy passes back through the OCT probe 122 
into the splitter 119 via Port 3. The reflected light energy that 
is returned into Port 2 and Port 3 of the splitter 119 recom 
bines and interferes according to the split ratio. The light 
recombines either constructively or destructively, depending 
on the difference of pathlengths. A series of constructive and 
destructive combinations of reflected light create an interfero 
gram (a plot of detector response as a function of optical path 
length difference). Each reflecting layer from the subject 121 
and the blood flow will generate an interferogram. The splitter 
119 can recombine light energy that is returned through Port 
2 and Port 3 so that the light energies interfere. The light 
energy is recombined in the reverse of the split ratio. For 
example, if a 60/40 split ratio, only 40% of the light energy 
returned through Port 2 and 60% of the light energy returned 
through Port 3 would be recombined. The recombined 
reflected light energy is directed out Port 4 of the splitter 119 
into a coupling lens 124. The coupling lens 124 receives light 
from the output of the splitter 119 and sets the beam etendue 
(beam diameter and divergence) to match that of the optical 
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spectrometer 125. The coupling lens 124 couples the light 
into an optical spectrometer 125. The optical spectrometer 
125 can divide the recombined reflected light energy light 
into different optical frequencies and direct them to different 
points in space which are detected by a line scan camera 126. 
The line scan camera 126 performs light to electrical trans 
duction resulting in digital light signal data 108. The digital 
light signal data 108 is transferred into the computer 101 via 
the OCT input interface 111. Interface between the line scan 
camera 126 and computer 101 can be a Universal Serial Bus 
(USB), or the like. The digital light signal data 108 can be 
stored in the mass storage device 104 or system memory 112 
and utilized by the image construction software 106 and the 
Labview image construction software 107. 
The image construction Software 106 can generate an 
image of the blood flow of subject 121 from the light signal 
data 108, by receiving light signal data 108 generating ampli 
tude and phase data. The amplitude and phase data (optical 
path length difference (ct) or optical time-delay (t)) can be 
separated into discrete channels and a plot of intensity Vs. 
depth (or amplitude VS. depth) can be generated for each 
channel. Such plot is known as an A-Scan, where the compo 
sition of all the A-scans can comprise one image. And move 
ment image construction Software 107 generates an image of 
the movement of the hemoglobin from the light signal data 
108. The movement image construction software 107 
receives light signal data 108 for at least two successive 
sweeps of the light source 117 and the light source performs 
a Fourier transform on the light signal data 108 generating 
amplitude and phase data. 
Optionally, additional information can be extracted from 
the light signal data to generate additional images. The light 
signal data can be further processed to generate a Stokes 
parameter polarimetric image when used in conjunction with 
polarization detectors and polarizing splitters to extract polar 
ization data from the light signal 108, as readily known to one 
skilled in the art of optical coherence tomography. The dif 
ferential phase OCT image data is shown in FIG.7, indicating 
the optical path difference with time variation of the magnetic 
field magnitude. Signal processing filters can be utilized to 
reduce the noise of the optical pathlength signal. 
Alternatively, the phase sensitive OCT system 100 can be 
configured for swept source OCT, which is a different type of 
spectral domain OCT. In swept source OCT, a tunable laser 
source replaces the broadband laser light source 117. The 
scanning rate can be at wavelengths of 800 nm-1500 nm. 
Also, the reference reflector surface 120 is in-line with 
sample path 120. The optical spectrometer 125 and line scan 
camera 126 are replaced with a general photodetector. In this 
configuration, an optical clock is used to triggeracquisition of 
the signal produced by the photodetector. The optical clock 
provides a set of uniformly spaced clock pulses with fixed 
intervals of optical frequency and at least one reference pulse. 
The fixed intervals of optical frequency are configured and 
specified in the optical clock to give a uniform train of pulses. 
The at least one reference pulse generated by the optical clock 
is utilized to provide a reference optical frequency or a trigger 
pulse. For example, the first reference pulse generated by the 
optical clock can correspond to an absorption line in a gas cell 
(e.g., Hydrogen Fluoride or Hydrogen Bromide). In this case 
the gas absorption line has a known optical frequency. The 
well-known absorption fingerprint bands in the HF gas cell 
result in a reduced detected intensity in the light transmitted 
through the gas cell, and as Such provide a metric on the 
absolute lasing wavelength at the digitized samples of the 
photodetector signal. The digitized sample number or Sam 













at one or more samples, depending on the number of absorp 
tion lines. The detected wavemeter photocurrent signal and 
the detected gas cell photocurrent signal are combined in the 
digitizer to provide the relationship between the sample num 
ber or sampling time and lasing wavelength throughout the 
entire Sweep. The detected photocurrent signal from the gas 
cell is digitized concurrently with the OCT interferogram and 
correlated with the known HF fingerprint to determine the 
wavenumber bias (k) of the swept source laser. Knowledge 
of wavenumber bias (k) allows accurate determination of the 
absolute wavenumber of each digitized sample throughout 
the spectral Sweep, effectively removing any wavenumber 
offsets and/or phase instabilities in the laser source, waveme 
ter and sampling electronics. Knowledge of the magnitude of 
the fixed intervals and the optical frequency of at least one 
clock pulse provides knowledge of the optical frequency of 
every clock pulse provided by the optical clock. 
In one configuration of an optical clock, an optical comb 
Source may be used. An optical comb source provides light 
with a power spectral density that is uniformly spaced in the 
optical frequency domain at a fixed, known, and stable optical 
frequency interval. By mixing or interfering light emitted by 
the tunable laser source with light emitted by the optical 
clock, the interference signal provides an optical clock pulse. 
In this configuration, the instantaneous spectral linewidth of 
the tunable laser source is less than the optical frequency 
interval of the optical comb source. In addition, at least one of 
the clock pulses generated by the optical clock is utilized to 
provide a reference optical frequency. For example, the first 
clock pulse generated by the optical clock can correspond to 
an absorption line in a gas cell (e.g., Hydrogen Fluoride). In 
this case the gas absorption line has a known optical fre 
quency. Knowledge of the magnitude of the fixed intervals 
and the optical frequency of at least one clock pulse provides 
knowledge of the optical frequency of every clock pulse 
provided by the optical clock. 
In another configuration of an optical clock, a Fabry-Perot 
interferometer is used. In this configuration, light emitted by 
the tunable laser source is input into the Fabry-Perot interfer 
ometer. The light transmitted through the Fabry-Perot inter 
ferometer provides light with a power spectral density that is 
uniformly spaced in the optical frequency domain at a fixed 
optical frequency interval. In this configuration, the instanta 
neous spectral linewidth of the tunable laser source is less 
than the optical frequency interval of Fabry-Perot interferom 
eter. In addition, at least one of the clock pulses generated by 
the optical clock is utilized to provide a reference optical 
frequency. For example, the first clock pulse generated by the 
optical clock can correspond to an absorption line in a gas cell 
(e.g., Hydrogen Fluoride). In this case the gas absorption line 
has a known optical frequency. Knowledge of the magnitude 
of the fixed intervals and the optical frequency of at least one 
clock pulse provides knowledge of the optical frequency of 
every clock pulse provided by the optical clock. 
In another embodiment, an enhanced detection of cancer 
with ultrasound imaging 200 is provided. Ultrasonography is 
the ultrasound-based diagnostic imaging technique used to 
visualize muscles and internal organs, their size, structures 
and any pathological lesions. “Ultrasound applies to all 
acoustic energy with a frequency above human hearing 
(20,000 Hertz or 20 kilohertz). Typical diagnostic sonogra 
phy scanners operate in the frequency range of 2 to 40 mega 
hertz, hundreds of times greater than this limit. The choice of 
frequency is a trade-off between the image spatial resolution 
and penetration depth into the patient, with lower frequencies 
giving less resolution and greater imaging depth. Doppler 
ultrasonography uses the Doppler Effect to assess whether 
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blood is moving towards or away from a probe, and its relative 
Velocity. By calculating the frequency shift (u) of a particu 
lar sample volume, for example a jet of blood flow over a heart 
valve, its speed and direction can be determined and visual 
ized. Ultrasonagraphy and Doppler Ultrasonagraphy can best 
be understood by S. A. Kana Introduction to physics in mod 
ern medicine, Taylor & Francis, (2003). The basic physics of 
the Doppler effect involving acoustic and electromagnetic 
waves of OCT is similar and many of the signal processing 
techniques (hardware and software) used to estimate the Dop 
pler shift of ultrasonic and optical coherence tomography 
signals is analogous. 
In one embodiment of the invention, an ultrasound probe 
212 is coupled with the magnetic field generator 100, as 
shown in FIG.8. Ultrasound 210 is directed into the body of 
the patient by known techniques and the moving red blood 
cells backscatter the ultrasonic energy back towards the trans 
ducer of the ultrasound. The oscillating magnetic field gen 
erated by the magnetic field generator 62 increases the con 
trast of the ultrasonic energy 210 received from the red blood 
cells. The transducer then converts the back-scattered ultra 
Sonic energy 210 into an electrical signal that is processed in 
Some known manner to determine an estimate of the flow. An 
enhanced ultrasound image is produced, as displayed in FIG. 
9. 
In one example, a rectal ultrasound probe is coupled with a 
magnet to evaluate the prostate gland for cancer. Currently, 
ultrasound is used for prostate cancer screening; however, the 
approach provides poor sensitivity and specificity. Yet, all 
cancers are known in the art to be highly vascular, so then the 
application of the magnetic field by generator 62 coupled 
with ultrasound enhances the contrast available from the 
endogenous RBC's in the prostate for cancer detection at an 
earlier stage. It is generally known in the art that tissues with 
cancerous cells have enhanced metabolic demand compared 
to normal tissues, so then cancerous cells have higher oxygen 
content from hemoglobin and a greater concentration of 
deoxygenated hemoglobin compared to normal tissues. An 
exemplary ultrasound image for prostate cancer Screening is 
shown in FIG. 9. 
MM-ODT. OCT, and ultrasound coupled with an oscillat 
ing magnetic field all can be used in clinical management of 
patients who need microvasculature or vasculature monitor 
ing, as shown in FIG. 10. The images could monitor and 
determine tissue perfusion and viability before, during and 
after therapeutic procedures. For example, the images could 
be used to detect oxygenated and deoxygenated blood Supply, 
detect blood vessel location, spatial extent of cancer, Vascular 
tissue abnormality identification, and imaging of port-wine 
stain. Alternatively, the images could monitor photodynamic 
therapy or evaluate cranial injuries. While medical applica 
tions of the invention have been described, the embodiments 
of the invention are applicable to any circumstance where 
image contrast is needed for fluids comprising endogenous 
metallic compositions. MM-ODT, OCT, and ultrasound can 
be used in various combinations to detect vascular occur 
CCS. 
OCT Imaging Using Nanoparticles 
Provided herein are methods, compositions and appara 
tuses for detecting a cell and/or a metallic composition using 
optical coherence tomography (“OCT). By a “cell' is meant 
one or more cell of or derived from, a living organism or 
subject. The cell or cells can be located within a subject or can 
be located ex vivo. The disclosed methods, compositions and 
apparatuses for detecting a cell and/or a metallic composition 
are described herein variously by reference to cell(s), com 













stood that description of various aspects of the disclosed 
methods, compositions and apparatuses by reference to one 
or a Subset of cell(s), composition(s) or metallic composi 
tion(s) constitutes description of that aspect of the disclosed 
methods, compositions and apparatuses to the non-refer 
enced cell(s), composition(s) and metallic composition(s), 
unless the context clearly indicates otherwise. 
An exemplary method for detecting a cell comprises apply 
ing a magnetic field to the cell. A cell can comprise a cellular 
membrane and a metallic composition. Optionally, the metal 
lic composition is a metallic nanoparticle that was adminis 
tered to the subject or otherwise brought into contact with the 
cell. Optionally, the metallic composition is hemoglobin, as 
discussed previously. 
The metallic composition can be located within the cell, 
including in the cell’s cellular membrane, or on the outside of 
the cell. If the metallic particle is located on the outside of the 
cell, it can be connected or targeted to the exterior surface of 
the cells cellular membrane. If the metallic composition is 
located within the cell, it may include inherent metallic com 
positions such as hemoglobin. Exemplary methods of target 
ing or connecting a metallic composition to a cell are 
described herein. 
The applied magnetic field can interact with a metallic 
composition located within the cell or located external and 
connected to the cell. The interaction of the magnetic field 
with the composition can cause a change in the cell. A change 
“in” the cell is not limited to changes internal to the cells 
cellular membrane. A change “in the cell is inclusive of 
changes within the cell, and also includes any change to, of, or 
in the cell caused by the interaction of the magnetic field with 
the composition. For example, changes that can occur "in the 
cell include movement of the cell, movement of one or more 
cell components, movement of the metallic composition, a 
change in the cellular membrane tension level of the cell, and 
a change in the internal strain field of the cell. Changes in the 
cell that cause changes, including those listed above, of 
neighboring or Surrounding cells or tissues can also be 
detected. Thus, changes in a cell can cause changes in Sur 
rounding cells or tissues. The changes in the Surrounding cells 
or tissues can be detected using the methods and systems 
described herein. Compositions located within or external to 
the cell can cause one or more detectable changes in the cell 
when contacted by an applied magnetic field. 
A detectable internal strain field can be generated in a cell 
when a metallic composition, including a metallic nanopar 
ticle, is under the action of an external force. The internal 
strain field can be detected using phase sensitive OCT using 
block correlation signal processing techniques that have been 
applied in elasticity imaging in ultrasound imaging. The 
external force may be provided by the application of an exter 
nal magnetic flux density (B). Action of the external force on 
each metallic composition can produce movement of the 
metallic composition (Z(t)) that produces a change in the 
cellular membrane tension level or an internal strain field 
within a cell. Action of a force on each metallic composition 
in a cell or tissues produces a movement of the metallic 
composition (Z(t)). Movement of the metallic composition 
can be along the Z-direction. The metallic composition can 
also have movement in any direction which may be written as 
vector displacement, u(r) for a metallic composition posi 
tioned at r. Metallic composition displacement u(r) can 
produce a displacement field (u(r,r)) in the proteins in the cell 
containing the metallic composition and Surrounding cells. In 
the case of a homogeneous elastic media, the displacement 
field (u(r,r)) can be computed for a semi-infinite half-space 
following, for example, the method of Mindlin (R. D. Mind 
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lin. A force at a point of a semi-infinite solid, Physics 1936, 
7:195-202, which is incorporated by reference for the meth 
ods taught therein). In the case of an inhomogenous vis 
coelastic media, a finite element method numerical approach 
can be applied to compute the displacement field in the cell. 
The displacement field (u(r,r)) produced by a metallic com 
position positioned at r can induce an internal stain field that 
is determined by change in the displacement field along a 
particular direction. The strain field (e.,(r,r)) is a tensor 
quantity and is given by, 
where u(r,r) is the i'th component of the displacement field 
and X, is the j" coordinate direction. For example, when j=3, 
X is the z-direction. The internal strain field in a cell due to all 
metallic compositions in the cell and Surrounding cells is a 
Superposition of the strain fields due to each metallic compo 
sition. A detectable change in a cell can also be caused with 
light energy. For example, pulsed laser light can be applied to 
contact a metallic particle comprised by the cell, where the 
metallic particle is included in a cell either naturally occur 
ring or administered exogenously and the metallic particle is 
affected by the pulsed laser light. The application of light 
energy can cause a detectable change in optical path due to a 
change in optical refractive and thermal elastic expansion. 
The light energy can also cause motion of the cell, particle, or 
tissues proximate to the cell for detection by optical coher 
ence tomography orphase sensitive optical coherence tomog 
raphy. Such movement can be caused by thermal elastic 
expansion. Alternatively, Sound energy can cause motion of 
the cell, particle, or tissues proximate to the cell for detection 
by optical coherence tomography or phase sensitive optical 
coherence tomography. 
The change in the cell can be detected using optical coher 
ence tomographic imaging modalities. Thus, the cell can be 
detected by detecting the change in the cell caused by the 
interaction of the magnetic field with the metallic composi 
tion using Such a modality. The change can be detected using 
a phase sensitive optical coherence tomographic imaging 
modality. Non-limiting examples of phase sensitive optical 
coherence tomographic (OCT) imaging modalities are 
described herein. Phase sensitive OCT imaging modalities 
can comprise a probe for transmitting and receiving light 
energy to and from the cell. The probe can be sized, shaped 
and otherwise configured for intravascular operation. The 
probe can further comprise a magnetic source for applying 
the magnetic field to the cell. The magnetic field can be 
applied to the cell from a magnetic source located external to 
the subject or internal to the subject. The external source can 
be located in a probe or can be distinct from a probe. 
Metallic Nanoparticles 
The metallic composition can comprise a plurality of 
metallic nanoparticles and/or a plurality of hemoglobin mol 
ecules. The nanoparticles can be substantially spherical in 
shape and can have a diameter from about 0.1 nanometers 
(nm) to about 1000.0 nm. The size of the tetrametric hemo 
globin protein is approximately 6 nm in diameter. The nano 
particles are not, however, limited to being spherical in shape. 
Thus, the nanoparticles are asymmetrical in shape. If the 
nanoparticles are asymmetrical in shape, the largest cross 
sectional dimension of the nanoparticles can be from about 
0.1 nanometers (nm) to about 1000.0 nm in length. The nano 














The metallic composition can comprise metal having non 
Zero magnetic Susceptibility or Zero magnetic Susceptibility 
or combinations of non-Zero and Zero magnetic Susceptibility 
metals. Thus, if the composition comprises nanoparticles, the 
nanoparticles can all have a non-Zero magnetic Susceptibility 
ora Zero magnetic susceptibility or a combination of particles 
having a non-Zero magnetic Susceptibility and a Zero mag 
netic susceptibility. Metallic compositions having a non-zero 
magnetic Susceptibility can comprise a material selected from 
the group consisting of iron oxide, iron, cobalt, nickel, chro 
mium and combinations thereof. The metallic compositions 
can comprise metal having non-Zero electrical conductivity 
or Zero electrical conductivity or combinations of non-zero 
and Zero electrical conductivity metals. Also provided is a 
method for detecting a composition, the method wherein the 
composition comprises a magnetic or paramagnetic material. 
Any magnetic or paramagnetic material, whether metallic or 
non-metallic, can be used in the described methods or with 
the described systems. In this regard, any material can be used 
that can cause a change in a cellor can be detected using phase 
sensitive optical coherence tomography when contacted with 
an applied magnetic field. Similarly, non-metallic, not mag 
netic particles can be used to cause a change in a cell or can be 
detected using phase sensitive optical coherence tomography 
when contacted with an applied magnetic field using the 
methods and systems described herein. 
The systems, apparatuses and methods can be practiced 
using metallic compositions without magnetic Susceptibility. 
When using metallic compositions without magnetic Suscep 
tibility, or when using compounds having a non-Zero mag 
netic susceptibility, an electrical eddy current can be induced 
in the composition. 
To induce an eddy current in a metallic composition a first 
time-varying magnetic field can be applied to a cell. The first 
magnetic field can interact with a metallic composition within 
or external to the cell to induce an electrical eddy current 
within the metallic composition. A second magnetic field can 
be applied to the cell that interacts with the induced eddy 
current to cause a change in the cell. The cell can be detected 
by detecting the change in the cell caused by the interaction of 
the second magnetic field with eddy current using a phase 
sensitive optical coherence tomographic imaging modality. 
Exemplary changes in the cell caused by the interaction of the 
second magnetic field with the eddy current include move 
ment of the cell, movement of the metallic composition, a 
change in the cellular membrane tension level, and a change 
in the internal strain field of the cell. 
Thus, a metallic composition or a nanoparticle that does 
not have a significant magnetic permeability can be used. For 
example, although gold nanoparticles do not have significant 
magnetic permeability many target-specific molecular agents 
(e.g., antibodies) can be conjugated to the nanoparticle Sur 
face. When using a high-conductivity particle for detection, a 
magnetic dipole can be induced in the particle by exposing to 
a time-varying magnetic field (B(t)). 
The time-varying magnetic field (B(t)) can cause an elec 
tromotive force or potential in the particle that can induce a 
Volumetric and Surface electric eddy-current in the high-con 
ductivity nanoparticle. Exemplary circuitry for a magnetic 
pulser that can be used to produce an eddy current is described 
in G H Schroder, Fast pulsed magnet systems, Handbook of 
Accelerator Physics and Engineering, A. Chao and M. Tinger, 
Eds. 1998 or in IEEE transactions on instrumentation and 
measurement, VOL. 54, NO. 6, December 2005, pp. 2481 
2485, which are incorporated herein by reference for the 
circuitry and methods described therein. 
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The eddy-current can produce time-varying magnetic 
moment that can interact with a second applied magnetic field 
(B). The induced eddy-current in the high-conductivity 
nanoparticle or metallic composition and the second applied 
magnetic field can interact to produce a torque or twist on the 
nanoparticle or metallic composition. The induced torque can 
twist the nanoparticle that is mechanically linked to a targetin 
the cell (e.g., the membrane) or located inside the cell. The 
twisting motion of the nanoparticle can modify the internal 
strainfield of the cell (surrounding cells and tissue) which can 
be detected using phase sensitive optical coherence tomogra 
phy. In this approach, phase-sensitive data can be recorded 
before and after application of a first field to induce an eddy 
current and block correlation algorithms can be used to com 
pute the depth resolved strain field in the tissue resulting from 
the motion of the nanoparticle or metallic composition. 
In exemplary embodiments, large magnetic fields can be 
generated by low temperature Superconducting magnets. 
These magnets need only be “charged once, maintained at a 
low temperature and do not require an external current to 
maintain the magnetic field. 
A metallic composition can be administered to the Subject. 
Administration of exogenous metallic compositions, for 
example, metallic nanoparticles is described in greater detail 
below. Optionally, the cell can be located within a subject and 
the metallic composition can be administered to the Subject. 
Optionally, the cell can be a macrophage and at least one 
metallic nanoparticle can be located within the macrophage 
or can be connected to the macrophage. The macrophage can 
be located in an atherosclerotic plaque within the subject. The 
macrophage can also be located within the eye of the Subject. 
The change in the cell caused by the interaction of the 
magnetic field with the metallic composition can be detected 
by generating a phase sensitive optical coherence tomo 
graphic image. A phase sensitive optical coherence tomo 
graphic image can comprise one or more lines of phase sen 
sitive light energy data captured using a phase sensitive 
optical coherence tomography modality, wherein at least one 
line is captured during the application of the magnetic field. 
One or more data line can be produced by generating light 
energy and transmitting at least a first portion of the generated 
light energy onto a reference reflector wherein at least a 
portion of the transmitted first portion of light energy is 
reflected by the reference reflector. At least a second portion 
of the generated light energy can be transmitted to contact the 
cell wherein at least a portion of the light energy that contacts 
the cell is reflected by the cell. The light energy reflected by 
the reference reflector and by the cell can be received, and the 
received light energy can be combined, and the received light 
energy can interfere. The combined light energy is processed 
to produce a phase sensitive optical coherence data line. 
One or more data lines can also be produced by generating 
light energy and transmitting at least a first portion of the 
generated light energy onto a reference reflector wherein at 
least a portion of the transmitted first portion of light energy 
is reflected by the reference reflector. At least a second portion 
of the generated light energy can be transmitted to contact the 
metallic composition wherein at least a portion of the light 
energy that contacts the metallic composition is reflected by 
the composition. The light energy reflected by the reference 
reflector and by the composition can be received. The 
received light energy can be combined, wherein the received 
light energy interferes. The combined light energy can be 
processed to produce the phase sensitive optical coherence 
data line. One or more data lines can also be produced by 
generating lightenergy and transmitting at least a first portion 













wherein at least a portion of the transmitted first portion of 
light energy is reflected by the reference reflector. At least a 
second portion of the generated light energy can be transmit 
ted to contact the metallic composition wherein at least a 
portion of the light energy that contacts the metallic compo 
sition is reflected by the composition. The light energy 
reflected by the reference reflector and by the composition 
can be received. The received light energy can be combined, 
wherein the received light energy interferes. The combined 
light energy can be processed to produce the phase sensitive 
optical coherence data line. The phase sensitive optical coher 
ence A-lines can be recorded before or after application of the 
stimulating field (magnetic, eddy-current, generation of 
pulsed light energy). Thus, the methods can further comprise 
recording reference phase sensitive optical coherence A-line 
prior to the non-lethal change and second phase sensitive 
optical coherence A-line during or after non-lethal change. 
The reference and second optical coherence A-line data can 
be correlated to quantify the non-lethal change. 
Phase sensitive light energy data lines can include the 
spectral dependent complex amplitude of light reflected from 
the cell, A(V), where v is the optical frequency of light. More 
precisely, what can be measured is product of the amplitudes 
of light reflected from the cell and reference: A(V): A(V)* 
where A(V)* is the conjugate of the spectrally-dependent 
complex amplitude of light reflected from the reference. The 
quantity A(V): A(V)* can be used to determine A(v) the 
phase sensitive amplitude of light backreflected from the 
cell/tissue at different time-delays t by using a time-fre 
quency transformation (e.g., Fourier). 
A plurality of phase sensitive optical coherence A-lines can 
be captured and used to construct an image. A phase sensitive 
image produced using the described systems and methods can 
have a phase sensitive resolution of at least about 30.0 nanom 
eters (nm), 25.0 nm, 15.0 nm, 10.0 nm, 5.0 nm, 4.0 nm, 3.0 
nm, or 2.0 nm. A plurality of phase sensitive optical coher 
ence A-lines can be spatially and temporally distinct and the 
image can comprise a B-mode image frame of at least two of 
the data lines. The plurality of phase sensitive light energy 
data lines can also be temporally distinct and the image can 
comprise an M-mode image comprising at least two of the 
lines. 
When a plurality of lines are used to create an image, at 
least a first phase sensitive light energy data line can be 
captured prior to the application of the magnetic field and at 
least a second phase sensitive light energy data line can be 
captured during application of the magnetic field, or generally 
the external stimulus. The magnetic field strength can be 
altered between the capture of data lines or between the 
capture of images. For example, at least a first phase sensitive 
light energy data line can be captured during the application 
of the magnetic field, wherein the magnetic field has a first 
predetermined strength and at least a second phase sensitive 
light energy data line during application of a second magnetic 
field having a second predetermined strength. The captured 
lines can be processed to create an image. Optionally, the first 
predetermined strength can be less than the second predeter 
mined strength. 
The described methods allows for the construction of both 
conventional intensity based OCT B-scan images and phase 
sensitive B-scan images. The phase sensitive B-scan images 
for viewing can correspond to changes in phase formed by at 
least two phase sensitive B-scan images corresponding to 
different magnetic field strengths (one of which can be zero 
magnetic field strength). At least two types of images can be 
viewed—one, a conventional intensity based OCT B-scan 
image and second a phase sensitive B-scan image formed by 
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the difference of two phase sensitive images recorded at dif 
ferent magnetic field strengths. 
Also provided are methods for detecting a composition 
comprising metal by applying a magnetic field to the compo 
sition, wherein the magnetic field interacts with the compo 
sition. The metallic composition can be detected using a 
phase sensitive optical coherence tomographic imaging 
modality. As described throughout, the composition can be 
located in a cellor can be connected to a cell. The composition 
can also be located in connection with non-cellular biological 
matter. For example, non-cellular biological matter can 
include a protein, a lipid, a peptide, and a nucleic acid. 
The methods of detecting cells and compositions using 
optical coherence tomography can comprise administering a 
plurality of metallic nanoparticles to a Subject or imaging 
nanoparticles present within a cell. 
Optionally, at least one administered nanoparticle localizes 
within a macrophage located in the Subject. At least one 
administered nanoparticle can also be optionally configured 
to localize to a target site in the Subject. Optionally, at least 
one nanoparticle is present within a cell. Optionally, the nano 
particle may be a hemoglobin molecule. 
In the methods described herein, a nanoparticle comprising 
a material with non-zero magnetic Susceptibility can be posi 
tionally moved in Vivo or invitro by an applied magnetic field. 
A material of non-zero magnetic susceptibility can include a 
variety of materials. For example, the nanoparticle can com 
prise any physiologically tolerable magnetic material or com 
binations thereof. The term magnetic material can optionally 
include any material displaying ferromagnetic, paramagnetic 
or Superparamagnetic properties. For example, the nanopar 
ticles can comprise a material selected from the group con 
sisting of iron oxide, iron, cobalt, nickel, and chromium. 
Metallic compositions as described throughout, including 
administered nanoparticles, can be magnetic. Optionally, a 
nanoparticle comprises iron oxide. When a nanoparticle com 
prises metal or magnetic materials, it can be moved while in 
the Subject using an internally or externally applied magnetic 
field, as described below. Any relevant metal with non-zero 
magnetic susceptibility or combinations thereof can be used. 
Many useable metals are known in the art; however, any metal 
displaying the desired characteristics can be used. Nanopar 
ticles can also comprise a combination of a material with a 
non-Zero magnetic Susceptibility and a material with a lower 
or Zero magnetic Susceptibility. For example, gold can be 
combined with higher magnetic Susceptibility materials (e.g., 
iron). For example, gold coated iron can be used. Nanopar 
ticles can also comprise polymers or other coating materials 
alone or in combination. Such polymers or coating materials 
can be used to attach targeting ligands, including but not 
limited to antibodies, as described below. When used in vivo, 
an administered nanoparticle can be physiologically tolerated 
by the subject, which can be readily determined by one skilled 
in the art. 
Nanoparticles can be solid, hollow or partially hollow and 
can be spherical or asymmetrical in shape. Optionally, the 
cross section of an asymmetric nanoparticle is oval or ellip 
tical. As one of skill in the art will appreciate, however, other 
asymmetric shapes can be used. The nanoparticles can com 
prise shelled or multi-shelled nanoparticles. Shelled or multi 
shelled nanoparticles can have targeting ligands conjugated 
to the shell material wherein the targeting ligand has an affin 
ity for or binds to a target site in a subject or ex vevo. Such 
shelled or multi-shelled nanoparticles can be made, for 
example, using techniques known in the art, for example, as 
described in Loo et al., “Nanoshell-Enabled Photonics-Based 













Treatment, (2004)3(1) 33-40, which is incorporated herein 
by reference for the methods taught herein. Further, Olden 
burg et al., “Nanoengineering of Optical Resonances.” 
Chemical Physics Letters (1998) 288, 243-247, is incorpo 
rated herein for methods of nanoshell synthesis. 
Localizing Nanoparticles 
A metallic composition, including a nanoparticle, can be 
configured to localize to a target site within the Subject. For 
example, the metallic composition can be configured to local 
ize to a neoplastic cell, to a peptide, to a protein, or to a nucleic 
acid. Optionally, the target site is an extracellular domain of a 
protein. A variety of cell types can also be targets of the 
metallic compositions. For example, target cells can be 
selected from one or more of a neoplastic cell, a squameous 
cell, a transitional cell, a basal cell, a muscle cell, an epithelial 
cell, and a mucosal cell. The target cells can also be located at 
different anatomical locations within a Subject. For example, 
the cell can be located in the Subject at an anatomical location 
selected from the group consisting of a lung, bronchus, intes 
tine, stomach, colon, eye, heart, blood vessel, cervix, bladder, 
urethra, skin, muscle, liver, kidney, and blood. 
One or more administered nanoparticle can localize to a 
desired target within the Subject using passive or active tar 
geting mechanisms. Passive targeting mechanisms take 
advantage of the Subjects inherent defense mechanisms to 
highlight phagocytic cells naturally responsible for particle 
clearance. For example, macrophage rich areas are a patho 
logical correlate to an unstable atherosclerotic plaque in a 
Subject. Moreover, administered nanoparticles, for example, 
Small Superparamagneitc and ultraSmall Superparamagnetic 
particles of iron oxide, are avidly taken up, or engulfed by, 
macrophages located in unstable plaques. Thus, through the 
Subject's natural defense mechanism, wherein macrophages 
accumulate in an unstable atherosclerotic plaque and engulf 
administered nanoparticles, administered nanoparticles can 
passively target the unstable plaque. Similarly, macrophages 
located in the eye of a subject can engulf nanoparticles. Such 
passive targeting of nanoparticles can be used with the meth 
ods and apparatuses described herein to highlight a plaque’s 
instability or to highlight other accumulation of phagocytic 
cells. 
Active targeting mechanisms can refer to the use of ligand 
directed, site-specific targeting of nanoparticles. A nanopar 
ticle can be configured to localize to a desired target site in a 
Subject using a wide variety of targeting ligands including, 
but not limited to, antibodies, polypeptides, peptides, nucleic 
acids, and polysaccharides. Such nanoparticles are referred to 
herein as “targeted nanoparticles. Targeting ligands or frag 
ments thereof can be used to target a nanoparticle to cellular, 
or other endogenous or exogenous biomarkers in the Subject. 
Such a biomarkers or “target sites’ can include, but are not 
limited to, proteins, polypeptides, peptides, polysaccharides, 
lipids, or antigenic portions thereof, which are expressed 
within the Subject. When active targeting mechanisms are 
used to target a cell, the targeted nanoparticle can be option 
ally internalized by the targeted cell. 
Thus, using the disclosed methods, at least one adminis 
tered nanoparticle can optionally localize within a macroph 
age located in the Subject and/or at least one administered 
targeted nanoparticle can localize to a desired target site in the 
Subject. 
The methods and apparatuses are not, however, limited to 
in vivo administration to a Subject. As would be clear to one 
skilled in the art, nanoparticles, including targeted nanopar 
ticles, can be administered in vitro to an ex vivo sample with 
localization of the nanoparticle to a desired target site and 
Subsequent imaging occurring in vitro. Moreover, a compo 
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sition, including at least one nanoparticle can be administered 
to a Subject in Vivo, and a sample can be Subsequently taken 
from the Subject and imaged ex vivo using the methods, 
systems, and apparatuses described herein. 
When using a targeted nanoparticle the target site in Vivo or 
in vitro can be endogenous or exogenous. The target site can 
be selected from the group consisting of an organ, cell, cell 
type, blood vessel, thrombus, fibrin and infective agent anti 
gens or portions thereof. Optionally, the target site can be a 
neoplastic cell. The target site can also be an extracellular 
domain of a protein. Furthermore, the target site can be 
selected from the group consisting of a lung, bronchus, intes 
tine, Stomach, colon, heart, brain, blood vessel, cervix, blad 
der, urethra, skin, muscle, liver, kidney and blood. The target 
site can also be a cell. For example, a cell can be selected from 
the group consisting of, but not limited to, a neoplastic cell, a 
squameous cell, a transitional cell, a basal cell, a muscle cell, 
an epithelial cell, a lymphocyte, a leukocyte, a monocyte, a 
red blood cell, and a mucosal cell. 
Thus, targeted nanoparticles can be targeted to a variety of 
cells, cell types, antigens (endogenous and exogenous), 
epitopes, cellular membrane proteins, organs, markers, tumor 
markers, angiogenesis markers, blood vessels, thrombus, 
fibrin, and infective agents. For example, targeted nanopar 
ticles can be produced that localize to targets expressed in a 
Subject. Optionally, the target can be a protein, and can be a 
protein with an extracellular or transmembrane domain. 
Optionally, the target can be the extracellular domain of a 
protein. 
Desired targets can be based on, but not limited to, the 
molecular signature of various pathologies, organs and/or 
cells. For example, adhesion molecules such as integrin 
CVB3, intercellular adhesion molecule-1 (I-CAM-1), fibrino 
gen receptor GPIb/IIIa and VEGF receptors are expressed in 
regions of angiogenesis, inflammation or thrombus. These 
molecular signatures can be used to localize nanoparticles 
through the use of a targeting ligand. The methods described 
herein optionally use nanoparticles targeted to one or more of 
VEGFR2, I-CAM-1, CVB3 integrin, C.V integrin, fibrinogen 
receptor GPIb/IIIa, P-selectin, and/or mucosal vascular 
adressin cell adhesion molecule-1. 
As used in this invention, the term "epitope' is meant to 
include any determinant capable of specific interaction with a 
targeting ligand as described below. Epitopic determinants 
can consist of chemically active Surface groupings of mol 
ecules Such as amino acids or Sugar side chains and can have 
specific three dimensional structural characteristics, as well 
as specific charge characteristics. 
Targeting ligands specific for a molecule that is expressed 
or over-expressed in a cell, tissue, or organ targeted for imag 
ing, Such as pre-cancerous, cancerous, neoplastic, or hyper 
proliferative cells, tissues, or organs, can be used with the 
nanoparticles described herein. This use can include the in 
Vivo or in vitro imaging, detection, or diagnosis of pre-can 
cerous, cancerous, neoplastic or hyperproliferative cells in a 
tissue or organ. The compositions and methods of the inven 
tion can be used or provided in diagnostic kits for use in 
detecting and diagnosing cancer. 
As used herein, a targeted cancer to be imaged, detected or 
diagnosed can be selected from, but are not limited to, the 
group comprising lymphomas (Hodgkins and non 
Hodgkins), B cell lymphoma, T cell lymphoma, myeloid 
leukemia, leukemias, mycosis fungoides, carcinomas, carci 
nomas of solid tissues, squamous cell carcinomas, adenocar 
cinomas, sarcomas, gliomas, blastomas, neuroblastomas, 
plasmacytomas, histiocytomas, melanomas, adenomas, 














comas, metastatic cancers, bladder cancer, brain cancer, ner 
Vous system cancer, squamous cell carcinoma of head and 
neck, neuroblastoma/glioblastoma, ovarian cancer, skin can 
cer, liver cancer, melanoma, squamous cell carcinomas of the 
mouth, throat, larynx, and lung, colon cancer, cervical cancer, 
cervical carcinoma, breast cancer, epithelial cancer, renal 
cancer, genitourinary cancer, pulmonary cancer, esophageal 
carcinoma, head and neck carcinoma, hematopoietic cancers, 
testicular cancer, colo-rectal cancers, prostatic cancer, or pan 
creatic cancer. 
Pre-cancerous conditions to be imaged, detected or diag 
nosed include, but are not limited to, cervical and anal dys 
plasias, other dysplasias, severe dysplasias, hyperplasias, 
atypical hyperplasias, and neoplasias. As would be clear to 
one skilled in the art, however, additional cancers and pre 
cancerous conditions can be imaged, detected or diagnosed 
using the methods and apparatuses described herein. 
Using methods known in the art, and as described herein, 
targeting ligands, such as polyclonal or monoclonal antibod 
ies, can be produced to desired target sites in a Subject. Thus, 
a targeted nanoparticle can further comprise an antibody or a 
fragment thereof. Methods for preparing and characterizing 
antibodies are well known in the art (See, e.g., Antibodies: A 
Laboratory Manual, Cold Spring Harbor Laboratory, 1988: 
incorporated herein by reference for the methods taught 
therein). 
Monoclonal antibodies can be obtained from a population 
of Substantially homogeneous antibodies, i.e., the individual 
antibodies comprising the population are identical except for 
possible naturally-occurring mutations that can be present in 
minor amounts. Thus, the modifier "monoclonal” indicates 
the character of the antibody as not being a mixture of discrete 
antibodies. 
For example, the monoclonal antibodies of the invention 
can be made using the hybridoma method first described by 
Kohler & Milstein, Nature 256:495 (1975), or can be made by 
recombinant DNA methods (Cabilly, et al., U.S. Pat. No. 
4,816,567). 
In the hybridoma method, a mouse or other appropriate 
host animal. Such as hamster can be immunized to elicit 
lymphocytes that produce or are capable of producing anti 
bodies that will specifically bind to the antigen used for 
immunization. Alternatively, lymphocytes can be immunized 
in vitro. Lymphocytes can be then fused with myeloma cells 
using a suitable fusing agent, such as polyethylene glycol, to 
form a hybridoma cell (Goding, Monoclonal Antibodies: 
Principles and Practice, pp. 59-103 (Academic Press, 1986)). 
DNA encoding a monoclonal antibody can be readily iso 
lated and sequenced using conventional procedures (e.g., by 
using oligonucleotide probes that are capable of binding spe 
cifically to genes encoding the heavy and light chains of 
murine antibodies). The hybridoma cells can serve as a pre 
ferred source of such DNA. Once isolated, the DNA can be 
placed into expression vectors, which can then be transfected 
into host cells such as simian COS cells, Chinese hamster 
ovary (CHO) cells, or myeloma cells that do not otherwise 
produce immunoglobulin protein, to obtain the synthesis of 
monoclonal antibodies in the recombinant host cells. The 
DNA also can be modified, for example, by substituting the 
coding sequence for human heavy and light chain constant 
domains in place of the homologous murine sequences, Mor 
rison, et al., Proc. Nat. Acad. Sci. 81, 6851 (1984), or by 
covalently joining to the immunoglobulin coding sequence 
all or part of the coding sequence for a non-immunoglobulin 
polypeptide. In that manner, "chimeric' or “hybrid' antibod 
ies can be prepared that have the binding specificity of an 
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anti-cancer, pre-cancer, or hyperproliferative cell or other 
target molecule. Optionally, the antibody used herein is 
“humanized' or fully human. 
Non-immunoglobulin polypeptides can be substituted for 
the constant domains of an antibody of the invention, or they 
can be substituted for the variable domains of one antigen 
combining site of an antibody of the invention to create a 
chimeric bivalent antibody comprising one antigen-combin 
ing site having specificity for a first antigen and another 
antigen-combining site having specificity for a different anti 
gen. 
Chimeric or hybrid antibodies also can be prepared in vitro 
using known methods in synthetic protein chemistry, includ 
ing those involving crosslinking agents. 
Methods for humanizing non-human antibodies are well 
known in the art. Generally, a humanized antibody has one or 
more amino acid residues introduced into it from a source 
which is non-human. These non-human amino acid residues 
are often referred to as “import residues, which are typically 
taken from an “import' variable domain. Humanization can 
be essentially performed following the method of Winter and 
co-workers (Jones et al., Nature 321,522-525 (1986); Riech 
mann et al., Nature 332, 323-327 (1988); Verhoeyen et al., 
Science 239, 1534-1536 (1988)), by substituting rodent 
CDRs or CDR sequences for the corresponding sequences of 
a human antibody. Accordingly, Such "humanized' antibod 
ies are chimericantibodies, wherein Substantially less thanan 
intact human variable domain has been substituted by the 
corresponding sequence from a non-human species. In prac 
tice, humanized antibodies are typically human antibodies in 
which some CDR residues and possibly some FR residues are 
substituted by residues from analogous sites in rodent anti 
bodies. 
Antibodies can be humanized with retention of high affin 
ity for the target site antigen and other favorable biological 
properties. Humanized antibodies can be prepared by a pro 
cess of analysis of the parental sequences and various con 
ceptual humanized products using three dimensional models 
of the parental and humanized sequences. Three dimensional 
immunoglobulin models are commonly available and are 
familiar to those skilled in the art. Computer programs are 
available which illustrate and display probable three-dimen 
sional conformational structures of selected candidate immu 
noglobulin sequences. Inspection of these displays permits 
analysis of the likely role of the residues in the functioning of 
the candidate immunoglobulin sequence, i.e. the analysis of 
residues that influence the ability of the candidate immuno 
globulin to bind its antigen. In this way, FR residues can be 
selected and combined from the consensus and import 
sequence so that the desired antibody characteristic, Such as 
increased affinity for the target site antigen?s), can be 
achieved. In general, the CDR residues are directly and most 
Substantially involved in influencing antigen binding. 
Human monoclonal antibodies can be made by a hybri 
doma method. Human myeloma and mouse-human hetero 
myeloma cell lines for the production of human monoclonal 
antibodies have been described, for example, by Kozbor, J. 
Immunol. 133, 3001 (1984), and Brodeur, et al., Monoclonal 
Antibody Production Techniques and Applications, pp. 51-63 
(Marcel Dekker, Inc., New York, 1987). 
Transgenic animals (e.g., mice) can be used that are 
capable, upon immunization, of producing a repertoire of 
human antibodies in the absence of endogenous immunoglo 
bulin production. For example, it has been described that the 
homozygous deletion of the antibody heavy chain joining 
region (JH) gene in chimeric and germ-line mutant mice 














duction. Transfer of the human germ-line immunoglobulin 
gene array in Such germ-line mutant mice will result in the 
production of human antibodies upon antigen challenge. See, 
e.g. Jakobovits et al., Proc. Natl. Acad. Sci. USA 90, 2551 
255 (1993); Jakobovits et al., Nature 362, 255-258 (1993). 
Alternatively, phage display technology (McCafferty et al., 
Nature 348, 552-553 (1990)) can be used to produce human 
antibodies and antibody fragments in vitro, from immunoglo 
bulin variable (V) domain gene repertoires from unimmu 
nized donors. According to this technique, antibody V 
domain genes are cloned in-frame into eithera major or minor 
coat protein gene of a filamentous bacteriophage. Such as 
M13 orfa, and displayed as functional antibody fragments on 
the Surface of the phage particle. Because the filamentous 
particle contains a single-stranded DNA copy of the phage 
genome, selections based on the functional properties of the 
antibody also result in selection of the gene encoding the 
antibody exhibiting those properties. Thus, the phage mimics 
some of the properties of the B-cell. Phage display can be 
performed in a variety of formats; for their review see, e.g. 
Johnson, Kevin S, and Chiswell, David J. Current Opinion in 
Structural Biology 3, 564-571 (1993). Several sources of 
V-gene segments can be used for phage display. Clackson et 
al., Nature 352, 624-628 (1991) isolated a diverse array of 
anti-oxazolone antibodies from a small random combinato 
rial library of V genes derived from the spleens of immunized 
mice. A repertoire of V genes from unimmunized human 
donors can be constructed and antibodies to a diverse array of 
antigens (including self-antigens) can be isolated essentially 
following the techniques described by Marks et al., J. Mol. 
Biol. 222, 581-597 (1991), or Griffith et al., EMBO J. 12, 
725-734 (1993). In a natural immune response, antibody 
genes accumulate mutations at a high rate (somatic hypermu 
tation). Some of the changes introduced can confer higher 
affinity, and B cells displaying high-affinity Surface immuno 
globulin are preferentially replicated and differentiated dur 
ing Subsequent antigen challenge. This natural process can be 
mimicked by employing the technique known as "chain shuf 
fling” (Marks et al., Bio/Technol. 10,779-783 (1992)). In this 
method, the affinity of “primary' human antibodies obtained 
by phage display can be improved by sequentially replacing 
the heavy and light chain V region genes with repertoires of 
naturally occurring variants (repertoires) of V domain genes 
obtained from unimmunized donors. This technique allows 
the production of antibodies and antibody fragments with 
affinities in the nM range. A strategy for making very large 
phage antibody repertoires (also known as “the mother-of-all 
libraries') has been described by Waterhouse et al., Nucl. 
Acids Res. 21, 2265-2266 (1993), and the isolation of a high 
affinity human antibody directly from Such large phage 
library is reported by Griffith et al., EMBO J. (1994). Gene 
shuffling can also be used to derive human antibodies from 
rodent antibodies, where the human antibody has similar 
affinities and specificities to the starting rodent antibody. 
According to this method, which is also referred to as 
"epitope imprinting, the heavy or light chain V domain gene 
of rodent antibodies obtained by phage display technique is 
replaced with a repertoire of human V domain genes, creating 
rodent-human chimeras. Selection on antigen results in iso 
lation of human variable capable of restoring a functional 
antigen-binding site, i.e. the epitope governs (imprints) the 
choice of partner. When the process is repeated in order to 
replace the remaining rodent V domain, a human antibody is 
obtained (see PCT patent application WO 93/06213, pub 
lished Apr. 1, 1993). Unlike traditional humanization of 
rodent antibodies by CDR grafting, this technique provides 
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completely human antibodies, which have no framework or 
CDR residues of rodent origin. 
Bispecific antibodies are monoclonal, preferably human or 
humanized, antibodies that have binding specificities for at 
least two different antigens. One of the binding specificities is 
for a first antigen and the other one is for a second antigen. 
Traditionally, the recombinant production of bispecific 
antibodies is based on the coexpression of two immunoglo 
bulin heavy chain-light chain pairs, where the two heavy 
chains have different specificities (Millstein and Cuello, 
Nature 305, 537-539 (1983)). Because of the random assort 
ment of immunoglobulin heavy and light chains, these hybri 
domas (quadromas) produce a potential mixture of 10 differ 
ent antibody molecules, of which only one has the correct 
bispecific structure. The purification of the correct molecule, 
which is usually done by affinity chromatography steps, is 
rather cumbersome, and the product yields are low. Similar 
procedures are disclosed in PCT application publication No. 
WO93/08829 (published May 13, 1993), and in Traunecker 
et al., EMBO 10, 3655-3659 (1991). For further details of 
generating bispecific antibodies see, for example, Suresh et 
al., Methods in Enzymology 121, 210 (1986). 
Heteroconjugate antibodies are also within the scope of the 
described compositions and methods. Heteroconjugate anti 
bodies are composed of two covalently joined antibodies. 
Heteroconjugate antibodies can be made using any conve 
nient cross-linking methods. Suitable cross-linking agents 
are well known in the art, and are disclosed in U.S. Pat. No. 
4,676.980, along with a number of cross-linking techniques. 
A variety of immunoassay formats can be used to select 
antibodies that selectively bind with a desired target site or 
target site antigen. For example, Solid-phase ELISA immu 
noassays are routinely used to select antibodies selectively 
immunoreactive with a protein, protein variant, or fragment 
thereof. See Harlow and Lane. Antibodies, A Laboratory 
Manual. Cold Spring Harbor Publications, New York, (1988), 
for a description of immunoassay formats and conditions that 
could be used to determine selective binding. The binding 
affinity of a monoclonal antibody can, for example, be deter 
mined by the Scatchard analysis of Munson et al., Anal. 
Biochem., 107:220 (1980). 
Not only can a targeted nanoparticle comprise an antibody 
or fragment thereof, but a targeted nanoparticle can also com 
prise targeting ligand that is a polypeptide or a fragment 
thereof. Optionally, polypeptides that are internalized by tar 
get cells can be attached to the Surface of a nanoparticle. 
Ligands that are internalized can optionally be used for inter 
nalization of a nanoparticle into a target cell. A modified 
phage library can be use to screen for specific polypeptide 
sequences that are internalized by desired target cells. For 
example, using the methods described in Kelly et al., “Detec 
tion of Vascular Adhesion Molecule-1 Expression Using a 
Novel Multimodal Nanoparticle. Circulation Res., (2005) 
96:327-336, which is incorporated herein for the methods 
taught therein, polypeptides can be selected that are internal 
ized by VCAM-1 expressing cells or other cells expressing a 
ligand of interest. 
There are a number of methods for isolating proteins which 
can bind a desired target. For example, phage display libraries 
have been used to isolate numerous polypeptides that interact 
with a specific target. (See for example, U.S. Pat. Nos. 6,031, 
071; 5,824,520, 5,596,079; and 5,565,332 which are herein 
incorporated by reference at least for their material related to 
phage display and methods related to combinatorial chemis 













or fragments thereof that interact with a desired target. A 
targeted nanoparticle can also comprise a binding domain of 
an antibody or phage. 
The term “polypeptide' or "peptide' is used broadly herein 
to mean two or more amino acids linked by a peptide bond. 
The term “fragment' or “proteolytic fragment also is used 
herein to refer to a product that can be produced by a pro 
teolytic reaction on a polypeptide, i.e., a peptide produced 
upon cleavage of a peptide bond in the polypeptide. A frag 
ment can be produced by a proteolytic reaction, but it should 
be recognized that a fragment need not necessarily be pro 
duced by a proteolytic reaction but can be produced using 
methods of chemical synthesis or methods of recombinant 
DNA technology, to produce a synthetic peptide that is 
equivalent to a proteolytic fragment. It should be recognized 
that the term “polypeptide' is not used herein to Suggest a 
particular size or number of amino acids comprising the mol 
ecule, and that a polypeptide of the invention can contain up 
to several amino acid residues or more. 
A nanoparticle can bind selectively or specifically to a 
desired target site, and/or can be internalized by a target cell. 
Such selective or specific binding and/or internalization can 
be readily determined using the methods, systems and appa 
ratuses described herein. For example, selective or specific 
binding can be determined in vivo or invitro by administering 
a targeted nanoparticle and detecting an increase in light 
scattering from the nanoparticle bound to a desired target site 
or internalized into the desired target cell. Detection of light 
scattering can be measured using the systems and apparatuses 
described below. 
Thus, a targeted nanoparticle can be compared to a control 
nanoparticle having all the components of the targeted nano 
particle except the targeting characteristics, such as, for 
example, targeting ligand. By detecting phase sensitive image 
data from the targeted nanoparticle bound to a desired target 
site versus a control nanoparticle, the specificity or selectivity 
of binding or internalization can be determined. If an anti 
body, polypeptide, or fragment thereof, or other targeting 
ligand is used, selective or specific binding to a target can be 
determined based on Standard antigen/polypeptide/epitope/ 
antibody complementary binding relationships. Further, 
other controls can be used. For example, the specific or selec 
tive targeting of the nanoparticles can be determined by 
exposing targeted nanoparticles to a control tissue, which 
includes all the components of the test or Subject tissue except 
for the desired target ligand or epitope. To compare a control 
sample to a test sample, levels of light scattering can be 
detected by, for example, the systems described below and the 
difference in levels or location can be compared. 
A targeting ligand can be coupled to the Surface or shell of 
at least one of the nanoparticle. Targeted nanoparticles com 
prising targeting ligands can be produced by methods known 
in the art. For example ligands, including but not limited to, 
antibodies, peptides, polypeptides, or fragments thereof can 
be conjugated to the nanoparticle Surface. 
Any method known in the art for conjugating a targeting 
ligand to a nanoparticle can be employed, including, for 
example, those methods described by Hunter, et al., Nature 
144:945 (1962); David, et al., Biochemistry 13:1014 (1974): 
Pain, et al., J. Immunol. Meth. 40:219 (1981); and Nygren, J. 
Histochem. and Cytochem. 30:407 (1982). Established pro 
tocols have been developed for the labeling metallic nanopar 
ticles with a broad range of biomolecules, including protein 
A, avidin, Streptavidin, glucose oxidase, horseradish peroxi 
dase, and IgG (antibodies). Nanoparticles can be prepared 
with bioorganic molecules on their surface (DNA, antibodies, 
avidin, phospholipids, etc). The nanoparticles can be charac 
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terized, modified, and conjugated with organic and biomol 
ecules. Polymers or other intermediate molecules can be used 
to tetherantibodies or other targeting ligands to the Surface of 
nanoparticles. Methods of tethering ligands to nanoparticles 
are know in the art as described in, for example, Loo et al., 
“Nanoshell-Enabled Photonics-Based Imaging and Therapy 
of Cancer. Tech. Cancer Res. and Treatment, (2004) 3(1) 
33-40, which is incorporated herein by reference for the 
methods taught herein. 
Covalent binding of a targeting ligand to a nanoparticle can 
be achieved, for example, by direct condensation of existing 
side chains or by the incorporation of external bridging mol 
ecules. Many bivalent or polyvalent agents can be useful in 
coupling polypeptide molecules to other particles, nanopar 
ticles, proteins, peptides or amine functions. Examples of 
coupling agents are carbodiimides, diisocyanates, glutaralde 
hyde, diazobenzenes, and hexamethylene diamines. This list 
is not intended to be exhaustive of the various coupling agents 
known in the art but, rather, is exemplary of the more common 
coupling agents that can be used. 
Optionally, one can first derivatize an antibody if used, and 
then attach the nanoparticle to the derivatized product. As 
used herein, the term "derivatize' is used to describe the 
chemical modification of the antibody substrate with a suit 
able cross-linking agent. Examples of cross-linking agents 
for use in this manner include the disulfide-bond containing 
linkers SPDP (N-succinimidyl-3-(2-pyridyldithio)propi 
onate) and SMPT (4-succinimidyl-oxycarbonyl-C.-methyl-O. 
(2-pyridyldithio)toluene). 
Targeting ligands can also be conjugated to nanoparticles 
using methods including the preparation of biotinylated anti 
body molecules and their consequent interaction with strepta 
vidin/nanoparticle conjugates. This approach takes advan 
tage of strong biospecific interaction between biotin and 
streptavidin and known protocols for immobilization of 
streptavidin on nanoparticles. Polypeptides with thiol termi 
nated alkyl chains can be directly attached to the surface of 
nanoparticles using the procedures described in Elghanian, 
R., et al., Selective colorimetric detection of polynucleotides 
based on the distance-dependent optical properties of gold 
nanoparticles. Science, 1997. 277(5329): p. 1078-1080 (in 
corporated by reference for the methods taught therein). For 
conjugation procedure one can use a mixture of thiol termi 
nated polypeptides and relatively small mercaptoacetic mol 
ecules to avoid high density immobilization of the polypep 
tides. 
Targeted nanoparticles can be prepared with a biotinylated 
Surface and an avidinated antibody, peptide, polypeptide or 
fragment thereof can be attached to the nanoparticle Surface 
using avidin-biotin bridging chemistry. Avidinated nanopar 
ticles can be used and a biotinylated antibody or fragment 
thereof or another biotinylated targeting ligand or fragments 
thereof can be administered to a subject. For example, a 
biotinylated targeting ligand Such as an antibody, protein or 
other bioconjugate can be used. Thus, a biotinylated antibody, 
targeting ligand or molecule, or fragment thereof can bind to 
a desired target within a subject. Once bound to the desired 
target, the nanoparticle with an avidinated Surface can bind to 
the biotinylated antibody, targeting molecule, or fragment 
thereof. When bound in this way, light energy can be trans 
mitted to the bound nanoparticle, which can produce light 
scattering of the transmitted light. An avidinated nanoparticle 
can also be bound to a biotinylated antibody, targeting ligand 
or molecule, or fragment thereofprior to administration to the 
Subject. 
When using a targeted nanoparticle with a biotinylated 














administered to the subject. For example, a biotinylated tar 
geting ligand Such as an antibody, polypeptide or other bio 
conjugate, or fragment thereof, can be administered to a Sub 
ject and allowed to accumulate at a target site 
When a targeted nanoparticle with a biotinylated surface is 
used, an avidin linker molecule, which attaches to the bioti 
nylated targeting ligand can be administered to the Subject. 
Then, a targeted nanoparticle with a biotinylated shell can be 
administered to the Subject. The targeted nanoparticle binds 
to the avidin linker molecule, which is bound to the biotiny 
lated targeting ligand, which is itself bound to the desired 
target. In this way, a three step method can be used to target 
nanoparticles to a desired target. The targeting ligand can 
bind to all of the desired targets detailed above as would be 
clear to one skilled in the art. 
Nanoparticles, including targeted nanoparticles, can also 
comprise a variety of markers, detectable moieties, or labels. 
Thus, for example, a nanoparticle equipped with a targeting 
ligand attached to its surface can also include another detect 
able moiety or label. As used herein, the term “detectable 
moiety' is intended to mean any Suitable label, including, but 
not limited to, enzymes, fluorophores, biotin, chromophores, 
radioisotopes, colored particles, electrochemical, chemical 
modifying or chemiluminescent moieties. Common fluores 
cent moieties include fluorescein, cyanine dyes, coumarins, 
phycoerythrin, phycobiliproteins, dansyl chloride, Texas 
Red, and lanthanide complexes. Of course, the derivatives of 
these compounds are included as common fluorescent moi 
eties. 
The detection of the detectable moiety can be direct pro 
vided that the detectable moiety is itself detectable, such as, 
for example, in the case of fluorophores. Alternatively, the 
detection of the detectable moiety can be indirect. In the latter 
case, a second moiety reactable with the detectable moiety, 
itself being directly detectable can be employed. 
A composition, including at least one nanoparticle, can be 
administered to a subject orally, parenterally (e.g., intrave 
nously), by intramuscular injection, by intraperitoneal injec 
tion, transdermally, extracorporeally, topically or the like. 
Parenteral administration of a composition, if used, is gener 
ally characterized by injection. Injectables can be prepared in 
conventional forms, either as liquid Solutions or Suspensions, 
Solid forms suitable for solution of Suspension in liquid prior 
to injection, or as emulsions. 
The compositions, including nanoparticles, can be used in 
combination with a pharmaceutically acceptable carrier. By 
“pharmaceutically acceptable' is meant a material that is not 
biologically or otherwise undesirable, i.e., the material can be 
administered to a subject, along with the nanoparticle, with 
out causing any undesirable biological effects or interacting 
in a deleterious manner with any of the other components of 
the pharmaceutical composition in which it is contained. The 
carrier would naturally be selected to minimize any degrada 
tion of the active ingredient and to minimize any adverse side 
effects in the subject, as would be well known to one of skill 
in the art. 
Suitable carriers and their formulations are described in 
Remington: The Science and Practice of Pharmacy (19th ed.) 
ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 
1995. Typically, an appropriate amount of a pharmaceuti 
cally-acceptable salt is used in the formulation to render the 
formulation isotonic. Examples of the pharmaceutically-ac 
ceptable carrier include, but are not limited to, saline, Ring 
er's solution and dextrose solution. The pH of the solution is 
preferably from about 5.0 to about 8.0, and more preferably 
from about 7.0 to about 7.5. As described above, composi 
tions can be administered intravascularly. Administered com 
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positions can include carriers, thickeners, diluents, buffers, 
preservatives, Surface active agents and the like in addition to 
the composition of choice. Administered compositions can 
also include one or more active ingredients such as antimi 
crobial agents, anti-inflammatory agents, anesthetics, and the 
like. 
When used in the described methods, an effective amount 
of one of the compositions, including the nanoparticles, of the 
present invention can be determined by one skilled in the art. 
The specific effective dose level for any particular subject can 
depend upon a variety of factors including the type and loca 
tion of the target site, activity of the specific composition 
employed, the specific composition employed, the age, body 
weight, general health, sex and diet of the Subject, the time of 
administration, the route of administration, the rate of excre 
tion of the specific composition employed, the duration of the 
treatment, drugs used in combination or coincidental with the 
specific composition employed, and like factors well known 
in the medical arts. For example, it is well within the skill of 
the art to start doses of the composition at levels lower than 
those required to achieve the desired diagnostic or imaging 
effect and to gradually increase the dosage until the desired 
effect is achieved. If desired, an effective dose can be divided 
into multiple doses for purposes of administration. 
Depending on the exemplary factors above, on the compo 
sition used, on the intended target site for the composition, 
and whether active or passive targeting of the described com 
positions is used, the time between administration of the 
described compositions and the detection of the described 
nanoparticles within the Subject can vary. For example, detec 
tion of the described nanoparticles can be performed at one or 
more time seconds, minutes, hours, days, and/or weeks after 
administration of the compositions to the subject. When and 
how frequently methods of detection of an administered.com 
position are performed can be determined by one skilled in 
the art through routine administration and detection. 
OCT System 
Also provided herein are systems for detecting a cell or 
metallic composition. An exemplary system comprises a 
magnet for applying a magnetic field to a cell and a phase 
sensitive optical coherence tomographic imaging modality 
for detecting the cell and/or metallic composition. The phase 
sensitive optical coherence tomographic imaging modality 
can comprise a probe for transmitting and receiving light 
energy to and from the cell. The probe can be an intravascular 
probe. 
The phase sensitive optical coherence tomographic imag 
ing modality included in the system can comprise a light 
source, a light splitter, a probe and a reference reflector. The 
phase sensitive optical coherence tomographic imaging 
modality may include the light splitter, but does not need to 
include a light splitter, i.e. a light coupler and the like may be 
used. Light energy generated by the light source can be trans 
mitted to and split by the splitter for transmission to the 
reference reflector and to the probe. The probe can be con 
figured to transmit at least a portion of the light energy trans 
mitted thereto into a target cell and to receive reflected light 
energy from the target cell and the reference reflector can be 
configured to reflect at least a portion of the light energy 
transmitted thereto. The system can further include a proces 
sor for processing reflected light energy from the reference 
reflector and light energy received by the probe to produce a 
phase sensitive optical coherence A-line. The reference 
reflector can be located in the probe. 
Although the exemplary systems described also include a 
multitude of fibers in the sample path, the described systems 













having a multitude of fibers. Thus, Systems comprising one 
fiber and methods of using Such exemplary systems are cov 
ered. Optionally, an exemplary system comprises a probe 
having a single optical fiber and a rotary reflector in optical 
communication with the single optical fiber. 
FIG. 6 is a block diagram illustrating an exemplary system 
100 that can be used for performing the imaging methods with 
nanoparticles. The nanoparticles are imaged in the blood flow 
or in the surrounding blood vessels of the blood flow. These 
exemplary OCT systems are only examples of phase sensitive 
spectral domain OCT systems and are not intended to Suggest 
any limitation as to the scope of use or functionality of OCT 
architectures. Neither should the OCT systems be interpreted 
as having any dependency nor a requirement relating to any 
one or combination of components illustrated in the exem 
plary OCT systems. 
The OCT system 100 of FIG. 6 includes a general-purpose 
computing device in the form of a computer 101. The com 
ponents of the computer 101 can include, but are not limited 
to, one or more processors or processing units 103, a system 
memory 112, and a system bus 113 that couples various 
system components including the processor 103 to the system 
memory 112. 
The system bus 113 represents one or more of several 
possible types of bus structures, including a memory bus or 
memory controller, a peripheral bus, an accelerated graphics 
port, and a processor or local bus using any of a variety of bus 
architectures. By way of example, such architectures can 
include an Industry Standard Architecture (ISA) bus, a Micro 
Channel Architecture (MCA) bus, an Enhanced ISA (EISA) 
bus, a Video Electronics Standards Association (VESA) local 
bus, and a Peripheral Component Interconnects (PCI) bus 
also known as a Mezzanine bus. This bus, and all buses 
specified in this description can also be implemented over a 
wired or wireless network connection. The bus 113, and all 
buses specified in this description can also be implemented 
over a wired or wireless network connection and each of the 
Subsystems, including the processor 103, a mass storage 
device 104, an operating system 105, an image construction 
Software 106, a nanoparticle movement image construction 
software 107, light signal data 108, the system memory 112, 
an OCT input interface 111, an OCT output interface 110, a 
display adapter 109, a display device 127, a human interface 
device 102, and a digital image capture device 117, can be 
contained within one or more remote computers (not shown) 
at physically separate locations, connected through buses of 
this form, in effect implementing a fully distributed system. 
The computer 101 can include a variety of computer read 
able media. Such media can be any available media that is 
accessible by the computer 101 and includes both volatile and 
non-volatile media, removable and non-removable media. 
The system memory 112 includes computer readable 
media in the form of volatile memory, such as random access 
memory (RAM), and/or non-volatile memory, such as read 
only memory (ROM). The system memory 112 typically 
contains data such as light signal data 108 and/or program 
modules Such as operating system 105, image construction 
software 106 and nanoparticle movement (or cellular mem 
brane tension level or intenial strain field change) image 
construction software 107 that are immediately accessible to 
and/or are presently operated on by the processing unit 103. 
Throughout this application the disclosed methods, compo 
sitions and apparatuses for detecting a cell and/or a metallic 
composition are described herein variously by reference to 
metallic particle movement, cellular movement, changes in 
cellular tension level, changes in internal Strain field of a 
cell, and change in neighboring or Surrounding cells and/or 
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tissues(s). It will be understood that description of various 
aspects of the disclosed methods, compositions and appara 
tuses by reference to detecting one or more of metallic par 
ticle movement, cellular movement, changes in cellular ten 
sion level, changes in internal Strain field of a cell, and change 
in neighboring or Surrounding cells and/or tissues(s) consti 
tutes description of that aspect of the disclosed methods, 
compositions and apparatuses to the non-referenced detec 
tion of metallic particle movement, cellular movement, 
changes in cellular tension level, changes in internal strain 
field of a cell, and change in neighboring or Surrounding cells 
and/or tissues(s), unless the context clearly indicates other 
wise. Thus, nanoparticle movement image construction soft 
ware can also include or alternatively include cellular move 
ment, changes in cellular tension level, changes in internal 
strain field of a cell, and change in neighboring or Surround 
ing cells and/or tissues(s) image construction Software. 
The computer 101 can also include other removable/non 
removable, Volatile/non-volatile computer storage media. By 
way of example, FIG. 6 illustrates a mass storage device 104 
which can provide non-volatile storage of computer code, 
computer readable instructions, data structures, program 
modules, and other data for the computer 101. For example, a 
mass storage device 104 can be a hard disk, a removable 
magnetic disk, a removable optical disk, magnetic cassettes 
or other magnetic storage devices, flash memory cards, CD 
ROM, digital versatile disks (DVD) or other optical storage, 
random access memories (RAM), read only memories 
(ROM), electrically erasable programmable read-only 
memory (EEPROM), and the like. 
Any number of program modules can be stored on the mass 
storage device 104, including by way of example, an operat 
ing system 105, image construction Software 106, nanopar 
ticle movement (or cellular membrane tension level or inter 
nal strain field change) image construction Software 107, and 
light signal data 108. Each of the operating system 105, image 
construction software 106, nanoparticle movement (or cellu 
lar membrane tension level or internal strain field change) 
image construction software 107, light signal data 108 (or 
Some combination thereof) can include elements of the pro 
gramming image construction software 106 and the nanopar 
ticle movement (or cellular membrane tension level or inter 
nal strain field change) image construction software 107. 
A user can enter commands and information into the com 
puter 101 via an input device (not shown). Examples of such 
input devices include, but are not limited to, a keyboard, 
pointing device (e.g., a “mouse'), a microphone, a joystick, a 
serial port, a scanner, and the like. These and other input 
devices can be connected to the processing unit 103 via a 
human machine interface 102 that is coupled to the system 
bus 113, but can be connected by other interface and bus 
structures, such as a parallel port, game port, or a universal 
serial bus (USB). 
A display device 127 can also be connected to the system 
bus 113 via an interface, such as a display adapter 109. For 
example, a display device can be a monitor. In addition to the 
display device 127, other output peripheral devices can 
include components such as speakers (not shown) and a 
printer (not shown) which can be connected to the computer 
101 via an input/output interface (not shown). 
The computer 101 can operate in a networked environment 
using logical connections to one or more remote computing 
devices (not shown). By way of example, a remote computing 
device can be a personal computer, portable computer, a 
server, a router, a network computer, a peer device or other 













Logical connections between the computer 101 and a 
remote computing device (not shown) can be made via a local 
area network (LAN) and a general wide area network (WAN). 
Such networking environments are commonplace in offices, 
enterprise-wide computer networks, intranets, and the Inter 
net. In a networked environment, image construction soft 
ware 106, nanoparticle movement (or cellular membrane ten 
sion level or internal strain field change) image construction 
software 107 and light signal data 108 depicted relative to the 
computer 101, or portions thereof, can be stored in a remote 
memory storage device (not shown). For purposes of illustra 
tion, application programs and other executable program 
components such as the operating system are illustrated 
herein as discrete blocks, although it is recognized that Such 
programs and components reside at various times in different 
storage components of the computing device 101, and are 
executed by the data processor(s) of the computer. 
An implementation of the image construction software 106 
and the nanoparticle movement (or cellular membrane ten 
sion level or internal strain field change) image construction 
software 107 can be stored on or transmitted across some 
form of computer readable media. Computer readable media 
can be any available media that can be accessed by a com 
puter. By way of example, and not limitation, computer read 
able media can comprise "computer storage media' and 
“communications media.” “Computer storage media” 
include Volatile and non-volatile, removable and non-remov 
able media implemented in any method or technology for 
storage of information Such as computer readable instruc 
tions, data structures, program modules, or other data. Com 
puter storage media includes, but is not limited to, RAM, 
ROM, EEPROM, flash memory or other memory technology, 
CD-ROM, digital versatile disks (DVD) or other optical stor 
age, magnetic cassettes, magnetic tape, magnetic disk storage 
or other magnetic storage devices, or any other medium 
which can be used to store the desired information and which 
can be accessed by a computer. 
The light signal data 108 can enter the computer 101 via the 
OCT input interface 111. The OCT output interface can be 
IEEE-488, IEEE-1 394, Universal Serial Bus (USB), or the 
like. The light. signal data 108 can be stored in mass storage 
device 104 and transferred to system memory 112 as light 
signal data 108 to be used by image construction software 106 
and nanoparticle movement (or cellular membrane tension 
level or internal strain field change) image construction soft 
ware 107. 
The OCT output interface 110 connects the computer 101 
to a magnet control 114. This connection can allow a user to 
regulate the current sent to a magnet 115 and a magnet 116 by 
the magnet control 114. The magnet control 114 directs cur 
rent flow into the magnets 115 or 116. The magnet control 114 
can work in conjunction with a line Scan camera 139 so that a 
user-specified field pulse sequence is present at the scanning 
site. 
FIG. 6 illustrates an example of a Phase Sensitive OCT 
system 100. The Phase Sensitive OCT system 100 can be 
utilized in conjunction with the computer and network archi 
tectures described above. 
The Phase Sensitive OCT system 100 can include agen 
eral-purpose computing device in the form of a computer 101 
and all subsystems of the computer 101, as previously 
described. The Phase Sensitive OCT system 100 can also 
include, as previously described, a display device 127, a 
magnet control 114, and a magnet 116. 
Light energy can be generated by a light source 117. The 
light source 117 can be abroadband laser light source coupled 
into optical fiber emitting light energy over a broad range of 
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optical frequencies. For example, the range can be from about 
400 nanometers to about 1600 nanometers. The light energy 
can be emitted over a multiplicity of optical wavelengths or 
frequencies. Alternatively, the light source can be a narrow 
band tunable laser light source wherein the optical wave 
lengths generated range from about 400 nanometers to about 
1600 nanometers. The light spectrum is continually varied in 
time, over a specified spectral region. As used herein, optical 
fiber can refer to glass or plastic wire or fiber. Optical fiber is 
indicated on FIG. 6 as lines connecting the various blocks of 
the figures. Where light energy is described as “passing.” 
“traveling,” “returning.” “directed,” or similar movement, 
Such movement can be via optical fiber. 
A fraction of the generated light energy passes from the 
light source 117 into an optical spectrum analyzer 118. The 
optical spectrum analyzer 118 measures optical frequency as 
the light energy is emitted from the light source 117 as a 
function of time. The optical spectrum analyzer 118 samples 
a portion of the light emitted by the light source 117. The 
optical spectrum analyzer 118 monitors the power spectral 
density of light entering the splitter 119. The remaining frac 
tion of light energy from the light Source 117 passes into a 
splitter 119. The splitter 119 can be a device with four ports. 
Port 1 allows light energy to enter the splitter 119. Ports 2 and 
3 allow light energy to leave and re-enter the splitter 119. Port 
4 allows light energy to leave the splitter 119. The splitter 119 
couples the light into Port 1. The splitter 119 divides the light 
according to a pre-determined split ratio selected by a user. 
For example, the split ratio can be 50/50 wherein half of the 
lightenergy entering the splitter 119 at Port 1 exits the splitter 
119 through Port 2 and half exits the splitter 119 through Port 
3. In another nonlimiting example, the split ratio can be 60/40 
wherein 60% of the light energy passes through Port 2 and 
40% of the light energy passes through Port 3. 
A fraction of the lightenergy (determined by the split ratio) 
that exits the splitter 119 through Port 2 travels to a reference 
reflector surface 120. The light energy is reflected from the 
reference reflector surface 120 back to the splitter 119 into 
Port 2. The reference reflector can be, by way of example, but 
not limitation, a planar metallic mirror or a multilayer dielec 
tric reflector with a specified spectral amplitude/phase reflec 
tivity. The remaining fraction of light that entered splitter 119 
through Port 1 exits splitter 119 through Port 3 and enters an 
OCT probe 122. The OCT probe 122 can be a turbine-type 
catheter as described in Patent Cooperation Treaty applica 
tion PCT/US04/12773 filed Apr. 23, 2004 which claims pri 
ority to U.S. provisional application 60/466.215 filed Apr. 28, 
2003, each herein incorporated by reference for the methods, 
apparatuses and systems taught therein. The OCT probe 122 
can be located within a subject 121 to allow light reflection off 
of subject 121 tissues and nanoparticles 123. 
The light energy that entered OCT probe 122 is reflected 
off of the tissue of subject 121 and nanoparticles 123. The 
reflected light energy passes back through the OCT probe 122 
into the splitter 119 via Port 3. The reflected light energy that 
is returned into Port 2 and Port 3 of the splitter 119 recom 
bines and interferes according to a split ratio. The light recom 
bines either constructively or destructively, depending on the 
difference of pathlengths. A series of constructive and 
destructive combinations of reflected light can be used to 
create an interferogram (a plot of detector response as a 
function of optical path length difference (ct) or optical time 
delay (t)). Each reflecting interface from the subject 121 and 
the nanoparticles can generate an interferogram. The splitter 
119 can recombine light energy that is returned through Port 
2 and Port 3 so that the light energies interfere. The light 













example, if a 60/40 split ratio, only 40% of the light energy 
returned through Port 2 and 60% of the light energy returned 
through Port 3 would be recombined. The recombined 
reflected light energy is directed out Port 4 of the splitter 119 
into a coupling lens 137. The coupling lens 124 receives light 
from the output of the splitter 119 and sets the beam etendue 
(beam diameter and divergence) to match that of the optical 
spectrometer 125. The coupling lens 124 couples the light 
into an optical spectrometer 125. The optical spectrometer 
125 can divide the recombined reflected light energy light 
into different optical frequencies and direct them to different 
points in space which are detected by a line scan camera 126. 
The line scan camera 126 performs light to electrical trans 
duction resulting in digital light signal data 108. The digital 
light signal data 108 is transferred into the computer 101 via 
the OCT Input interface 111. Interface between the line scan 
camera 126 and computer 101 can be, for example, IEEE 
488, IEEE-1394, Universal Serial Bus (USB), or the like. The 
digital light signal data 108 can be stored in the mass storage 
device 104 or system memory 112 and utilized by the image 
construction software 106 and the nanoparticle movement (or 
cellular membrane tension level or internal strain field 
change) image construction Software 107. 
The preceding exemplary phase sensitive OCT system is 
only one example of the contemplated systems for imaging 
tissues and nanoparticles. Variations in layout and equipment 
known to one skilled in the art are also contemplated. 
FIG. 18 is an exemplary block diagram of a Multi-Channel 
Phase Sensitive OCT system 2000. The exemplary Multi 
Channel Phase Sensitive OCT system 2000 can include a 
general-purpose computing device in the form of the com 
puter 101, and all subsystems of the computer 101, as 
described herein. The exemplary multi-channel Phase Sensi 
tive OCT system 2000 can also include, as previously 
described, a display device 127, a magnet control 114, and a 
magnet 114 or a magnet 115. 
Light energy is generated by a light Source 2120. The light 
Source 212 can be a narrow band tunable laser light source 
wherein the optical wavelengths generated range from about 
400 nanometers to about 1600 nanometers. Appropriate 
selection of a range of optical wavelengths can be readily 
determined by one skilled in the art. For example, if light 
energy is to go through Substantial water path, i.e., deep 
tissue, then an operator can select longer optical wavelengths. 
For example, 1300-1600 nanometers. The light spectrum is 
continuously varied in time, over a specified spectral region. 
A fraction of the light energy passes from the light source 
2120 into an optical spectrum analyzer 118. The optical spec 
trum analyzer 118 samples a portion of the light emitted by 
the light source 212. The optical spectrum analyzer 111 moni 
tors the power spectral density of light entering the circulator 
2010. The optical spectrum analyzer 118 can measure optical 
frequency as it is emitted from the light source 2120 as a 
function of time. The remaining fraction of light energy gen 
erated by the light source 2120 passes into a fiber circulator 
2010. The fiber circulator 201 can comprise three ports, des 
ignated Port 1, Port 2, and Port 3. Light energy can enter Port 
1. Light energy can exit and re-enter Port 2. Light energy can 
exit Port 3. The fiber circulator 2010 can recombine light 
energy that re-enters via Port 2. Light energy from the light 
source 2120 passes into the fiber circulator 2010 through Port 
1. The light energy exits the fiber circulator 2010 through Port 
2 and enters an OCT probe 2070. The light energy is coupled 
to a collimator lens 2020. The collimator lens 2020 focuses 
the light emitted from the fiberatapoint infinitely far from the 
fiber tip. 
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The light energy is collimated into a lens array 2030. The 
lens array 2030 can comprise a lattice of microlenses or 
lenslets. The number of microlenses in the lens array 2030 can 
be readily determined by one skilled in the art. For each 
microlens, there is a fiber channel 204 that is coupled to the 
microlens. Fiber channels 2040 are optical waveguides that 
confine and guide light along a path. The fiber channels 2040 
can be varied in length. Choosing an appropriate length for 
the fiber channels 2040 is known to one skilled in the art. The 
difference in the length between fiber channels 2040 can be 
from about one and a half to about ten times the scan depth in 
the tissue of a subject 121. This variable length can allow 
demultiplexing light signal detected from the channels. A 
fraction of the light energy transmitted into the fiber channels 
2040 is reflected from a reference reflector surface 120 back 
into the fiber channels 2040, through the lens array 2030, into 
the collimator lens 2020 and into the fiber circulator 2010. 
This reflected light energy can serve as a reference reflection. 
The light energy that is not reflected back from the reference 
reflector surface 120 passes through the reference reflector 
Surface 120 and onto an imaging lens 2050. The imaging lens 
2050 images the light energy from the tips of the fiber chan 
nels 2040 onto the tissue of the subject 121. The light energy 
passes through the imaging lens 2050 onto a reflector surface 
2060, which turns the light energy 90 degrees. This allows the 
light energy to be reflected out radially inside a tissue. There 
is one reflector Surface 2060 for each fiber channel 2040. The 
light energy that is turned 90 degrees by the reflector surface 
2060 is back reflected off of the tissue of subject 121, and 
nanoparticles 123. 
The light is reflected from the tissue of subject 121 and the 
nanoparticles 123. The light energy strikes the reflector Sur 
face 2060 and is turned back 90 degrees. The light energy is 
then coupled by the imaging lens 2050 through the reference 
reflector surface 120 and back into each fiber channel 2040. 
The light energy reflected from the nanoparticles 123 and the 
tissue of subject 121 recombines and interferes with the light 
reflected from the reference reflector surface 120 in the fiber 
channels 2040. The recombined light energy can be coupled 
back into the lens array 2030 through the collimator lens 2020 
and back into Port 2 of the fiber circulator 2010. The recom 
bined light energy exits the fiber circulator 2010 through Port 
3. A coupling lens 2080 couples the recombined light energy 
from the fiber circulator 2010 into a photo receiver 2090. The 
photo receiver 2090 converts the light energy signal into a 
Voltage signal that is proportional to the number of photons 
contained in the recombined light energy. The Voltage signal 
passes from the photo receiver 2090 into a pre?amp 2100. The 
pre?amp. 2100 takes the voltage signal and amplifies it. The 
amplified voltage signal enters an A/D converter 2110. The 
A/D converter 2110 digitizes the voltage signal. This digital 
light signal data then enters the computer 101 through the 
OCT input interface 111. The digital light signal data 108 can 
be stored in the mass storage device 104 or system memory 
112 and utilized by the image construction software 106 and 
the nanoparticle movement (or cellular membrane tension 
level or internal strainfield) image construction software 107. 
The method can further comprise generating light energy 
for at least two Successive Sweeps of light energy. A Sweep is 
an emission of light from a light Source across a range of 
optical frequencies. Multiple sweeps can be combined with 
application of a magnetic field to generate images with and 
without a magnetic field applied. 
The method can further comprise applying a magnetic field 
to the subject for each of the successive sweeps of the light 
energy wherein the strength of the magnetic field applied in a 
Sweep is greater than the strength of the magnetic field from 
the preceding Sweep and wherein the magnetic field causes 
movement of at least one of the metallic nanoparticles. The 














from a source external to the Subject or from a source internal 
to the Subject. A coil generating the magnetic field can be 
integrated into a catheter or can be external to the Subject of 
the scan. 
As shown in FIG. 18, a non-uniform magnetic field can be 
applied to the tissue of subject 121 and the nanoparticles 123. 
The non-uniform magnetic field can be applied by the magnet 
116, which can be a magnet internal to the OCT probe 122 or 
the non-uniform magnetic field can be applied externally to 
the Subject 121 by a magnet. Magnets 116 and external mag 
net are both controlled by magnet control 114. The magnet 
control can provide the current Source to power external mag 
net and magnet 116 and is under the control of the computer 
101. The magnet control 114 interfaces with the computer 
101 through the OCT output interface 110. The magnet con 
trol 114 can interface with the computer 101 via IEEE-488, 
IEEE-1394, Universal Serial Bus (USB), or the like. 
The method can further comprise processing the received 
light energy to produce a phase sensitive OCT image. The 
image produced can have a phase resolution of at least 30 
nanometers (nm). Phase resolution is defined as the phase 
delay of the light signal returning from the tissue scanned. For 
example, the image can have a phase resolution of about at 
least 30 nm, 25 nm, 20 nm, 15 nm, 10 nm, 5 nm, 4 nm, 3 nm, 
or 2 nm. 
The processing of the received light energy can be per 
formed by Software components. The image construction 
software 106 and the nanoparticle movement (or cellular 
membrane tension level or internal strain field) image con 
struction software 107 can be described in the general context 
of computer-executable instructions. Such as program mod 
ules, being executed by one or more computers or other 
devices. Generally, program modules include computer code, 
routines, programs, objects, components, data structures, etc. 
that perform particular tasks or implement particular abstract 
data types. The image construction software 106 and the 
nanoparticle movement (or cellular membrane tension level 
or internal strain field) image construction software 107 can 
also be practiced in distributed computing environments 
where tasks are performed by remote processing devices that 
are linked through a communications network. In a distrib 
uted computing environment, program modules can be 
located in both local and remote computer storage media 
including memory storage devices. 
The image construction Software 106 can generate an 
image of the tissue of Subject 121 from the light signal data 
108. The image construction software 106 can receive the 
light signal data 108 and can perform a time-frequency trans 
form (e.g. Fourier transform) on the light signal data 108 
generating amplitude and phase data. The amplitude and 
phase data (optical path length difference (ct) or optical time 
delay (t)) can be separated into discrete channels and a plot of 
intensity vs. depth (or amplitude vs. depth) can be generated 
for each channel. Such a plot is known in the art as an 'A' 
Scan. The composition of all the 'A' scans can comprise one 
image. 
The nanoparticle movement (or cellular membrane tension 
level or internal strain field) image construction software 107 
generates an image of the movement of the nanoparticles 123 
from the light signal data 108. The nanoparticle movement (or 
cellular membrane tension level or internal strain field) image 
construction software 107 receives the light signal data 108 
for at least two successive sweeps of the light source 117 or 
the light source 212 and performs a Fourier transform on the 
light signal data 108 generating amplitude and phase data. 
The amplitude and phase data can be separated into discrete 
channels, one channel for each fiber channel 204, and a plot of 
phase vs. depth (optical time-delay (t)) can be generated for 
each channel. Points of nanoparticle 123 movements are 
identified by the phase changes between two Successive 
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sweeps of the light source 117 or the light source 212 corre 
sponding to two applied magnetic field strengths. 
Optionally, an optical clock is used to trigger acquisition of 
the signal produced by the photodetector. The optical clock 
provides a set of uniformly spaced clock pulses with fixed 
intervals of optical frequency and at least one reference pulse. 
The fixed intervals of optical frequency are configured and 
specified in the optical clock to give a uniform train of pulses. 
The at least one reference pulse generated by the optical clock 
is utilized to provide a reference optical frequency or a trigger 
pulse. For example, the first reference pulse generated by the 
optical clock can correspond to an absorption line in a gas cell 
(e.g., Hydrogen Fluoride or Hydrogen Bromide). In this case 
the gas absorption line has a known optical frequency. The 
well-known absorption fingerprint bands in the HF gas cell 
result in a reduced detected intensity in the light transmitted 
through the gas cell, and as Such provide a metric on the 
absolute lasing wavelength at the digitized samples of the 
photodetector signal. The digitized sample number or Sam 
pling time scale canthus be converted to absolute wavelength 
at one or more samples, depending on the number of absorp 
tion lines. The detected wavemeter photocurrent signal and 
the detected gas cell photocurrent signal are combined in the 
digitizer to provide the relationship between the sample num 
ber or sampling time and lasing wavelength throughout the 
entire Sweep. The detected photocurrent signal from the gas 
cell is digitized concurrently with the OCT interferogram and 
correlated with the known HF fingerprint to determine the 
wavenumber bias (k) of the swept source laser. Knowledge 
of wavenumber bias (k) allows accurate determination of the 
absolute wavenumber of each digitized sample throughout 
the spectral Sweep, effectively removing any wavenumber 
offsets and/or phase instabilities in the laser source, waveme 
ter and sampling electronics. Knowledge of the magnitude of 
the fixed intervals and the optical frequency of at least one 
clock pulse provides knowledge of the optical frequency of 
every clock pulse provided by the optical clock. 
Optionally, additional information can be extracted from 
the light signal data 108 to generate additional images. The 
light signal data 108 can be further processed to extract the 
Doppler frequency shift as is readily known to one skilled in 
the art. The light signal data 108 can also be further processed 
to generate a Stokes parameter polarimetric image when used 
in conjunction with polarization sensitive OCT to extract 
polarization data from the light signal 108 as is readily known 
to one skilled in the art. 
The methods and systems can be used to perform molecu 
lar identification to stabilize vulnerable plaque that is antici 
pated to rupture and cause heart attacks, strokes, and progres 
sion of peripheral vascular disease. It can also be used to 
identify macrophages present in degenerative eye diseases 
which can lead to blindness and selectively kill these patho 
logic cells to stabilize the eye degeneration. Generally, many 
cancers are known to be associated with the presence of 
macrophages, and it may provide a method for early cancer 
detection and treatment. 
Example 2 
A solenoid coil with a ferrite core was used to apply a 
sinusoidal magnetic field to tissues taken from the liver of an 
ApoE-/-knockout mouse. One mouse was loaded with mag 
netic nanoparticles one week before imaging while an 
unloaded mouse served as a control. FIG. 11A shows a sole 
noid drive signal (top) and optical pathlength change (bot 
tom) observed in mouse loaded with nanoparticles. FIG. 11B 
shows a Solenoid drive signal (top) and optical pathlength 
change (bottom) observed in control mouse (no nanopar 
ticles). These data demonstrate that iron oxide particles that 













the mice. Moreover, the particles have put in motion with a 
magnet and detected with differential phase OCT using the 
systems and methods described herein. 
To calculate magnetic field strength a finite element 
method (FEM) can be used. Maxwell equations subjected to 
certain boundary conditions can be used to solve low-fre 
quency magnetostatic problems. The use and solution of 
Maxwell equations are described in, for example, Monk P. 
Finite Element Methods for Maxwell's Equations, Oxford 
University Press, 2003, which is incorporated in its entirety 
by reference. 
Maxwell equations can be written as: 
1.1 WX H = 1 + -- (1.1) 
WXE = --- (1.2) 
W. H = p (1.3) 
(1.4) 
In case of magnetostatic problems 
the magnetic field (H) and magnetic flux density (B) are 
satisfied with following equations: 
VXH=J (1.5) 
W. B=O (1.6) 
B and Hare subject to a generalized constitutive relation: 
Finite element methods (FEM) used magnetic vector 
potential (A) to find magnetic field strength. 
B=VXA (1.8) 
Equation (1.5) can be rewritten as 
From equation (1.9), magnetic field strength and flux den 
sity can be solved. The symbols and unit for electromagnetic 
quantities for solving FEM problems include: 
H: Magnetic field (Ampere/m) 
E: Electric field (Volt/meter) 
B: Magnetic flux density (Tesla) 
D: Electric flux density (Coulomb/meter) 
A: Magnetic potential (Weber/meter) 
M: Magnetization (Ampere/meter) 
u: Permeability of vacuum=4II107(H/m) 
WB = diR = 2B. : B +? it X ' ' ) 
(W. B is divergence of B) 
Magnetic fields of between about 0.5, 1.5 and 2.0 Tesla 
were used to cause movement of the nanoparticles. Magnetic 
fields between about 1.0 and 9.0 Tesla can also be used. The 
magnetic field used is typically higher if the tissue of interest 
comprises a greater number of nanoparticles or iron, when 
compared to tissue with fewer nanoparticles or iron. 
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Example 3 
Colloidal suspensions of SPIO nanoparticles are tissue 
specific MRI contrast agents approved by the United States 
Food and Drug Administration (FDA) for human use in 1997. 
SPIO particles are also known as Ferumoxides or AMI-25 and 
their trade name is Feridex(R. I.V. (USA) and EndoremR) 
(EU). Mean core diameter of these particles is 20 nm and total 
aggregation diameter is about 100 nm. SPIO nanoparticles 
comprise nonstoichiometric magnetite crystalline cores, iron, 
and dextran T-10 coating that is used to prevent aggregation 
and stabilization in the liver. 80% of injected dose of SPIO 
nanoparticles accumulate in tissue based macrophages 
(Kupffer cells) due to the relatively short blood half life 
compared to ultrasmall SPIO nanoparticles. Uptake of SPIO 
nanoparticles by macrophage cells is directly proportional to 
the intravenous injection (IV) concentration, blood half life, 
and core size. 
To evaluate magnetic force on Superparamagnetic (SPIO) 
nanoparticles, magnetic potential energy, U. can be used to 
calculate force due to application of an external magnetic flux 
density (B). 
U=-1.2m B (11) 
If a magnetic material is exposed to an external magnetic 
flux density, B, the individual particles have overall response 
determined by the magnetic moment, m. The magnetic flux 
density on magnetic nanoparticles can be written: 
where u(41x107 H/M) is the permeability of free space, 
and M is the magnetic moment per unit volume and H is 
magnetic field strength. The magnetic moment, m, acting on 
magnetic volume, V is given by, m=MV. Magnetization of 
magnetic particles can be classified in terms of the standard 
relation MXH. Therefore, magnetic moment m becomes: 
(13) 
In Eq. (13), susceptibility of the SPIO particles X is dimen 
sionless in SI units and given by dipole density for each 
paramagnetic material and is an important parameter charac 
terizing magnetic properties of SPIO nanoparticles. From Eq. 
(11), magnetic energy U. of a SPIO nanoparticles in external 
magnetic field is given by, 
(14) 
Magnetic force acting on SPIO nanoparticles becomes: 
(15) YB)= WW B2 - As V3, 
A sinusoidal magnetic flux density that is principally along 
the Z-direction was assumed. Hence, B(x, y, Z:t) sin (27tft) 
B.(z)k and the magnetic force F., acting on nanoparticles in 












where F is magnetic force, f, is the modulation frequency 
of the applied sinusoidal magnetic field, kZ(t) is an elastic 
restoring force, and 
is a viscous drag force that account for the viscoelastic prop 
erties of the local tissue environment. The negative sign of the 
Viscous drag and restoring force indicates that this force is in 
opposite direction to movement Z(t). Equation 17 can be 
written by dividing by the mass, m. 
of x(t), k(t) (18) -- r 33 As V. B 
812 i 1 - cos(4 ft).B.(z), not 2nto 
Equation 18 can be rewritten using the first terms in the 
Maclarin series for the magnetic field, 
d :(t) r 03, kz(t) V, a B.(0) (19) 
812 -- a? " - 2nto 1 - cos(47 ft).B. (O) 8. 
Letting 
As V. ÖB. (O) 
C 5, B.0) 33 
c=4. If the second order differential Eq. (19) can be written 
6:(t) (20) 
812 -- 
r 33 k:(t) 
-- mat - = a1 - cos(ct), 
The Laplace transform can be used to solve the second 
order differential equation (20), assuming Zero initial dis 
placements and Velocity to find; 
CS (21) *zis) + (szls) + Zs) = 2 S (s) + is (s) + (s) = - 2, 
C CS 
(s2 + 2) 1 S 
Z(S) = = a k k 
(+ is + i) (+ is + i) (+ is + i) it it it it it it 
By computing the Sum of the transforms, Z(s) can be 
derived in Eq. (21) 
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i 1 tr 
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(22) 
The displacement Z(t) of nanoparticles can be found by 
using an inverse Laplace transform; the solution includes 
transient and steady state terms. The initial motion of mag 
netic nanoparticles is driven by a constant magnetic force and 
displays a damped transient motion before steady state 
motion dominates at twice the modulation frequency (f) of 
the applied sinusoidal magnetic field. Motion of the nanopar 
ticles at double the modulation frequency originates from the 
magnetic force being proportional to the product of the field 
and field-gradient (Eq. 17). 
Liver tissues from 12 week old ApoE high fat fed mice 
were utilized because they contain tissue based macrophages 
cells. The mice were injected via the jugular vein with either 
Feridex I.V. (Ferumoxides injectable solutions: Berelex 
Laboratories, Montville, N.J.) for intravenous administration 
(1.0, 0.1, and 0.01 mmol Fe/kg body weight) or saline and 
sacrificed 2 days post intravenous injection. The mice were 
euthanized with a lethal dose of Ketamine and Xylazine. 
After euthanizing, abdominal incisions were made to remove 
the entire liver from the mouse. Portions were cut using a 
microtome. Physical thickness of the liversamples was 1 mm 
and 0.5 cmx0.5 cm in lateral dimensions. After completion of 
the DP-OCT measurements, the mouse livers were embedded 
in 10% formalin acid, and processed for histology. 5um thick 
sections were cut and stained with Prussian blue to identify 
iron deposition in liver Kupffer cells in mouse livertissues. To 
verify SPIO uptake by macrophage cells from histology 
slides, Image Pro Plus(R (Mediacynernetics Inc., Silver 
Spring, Md.) was used to measure the total area of liver and 
accumulated area of SPIO aggregation containing Prussian 
blue positive. 
FIGS. 12A and 12B shows a schematic diagram of a fiber 
based dual channel differential phase optical coherence 
tomography (DP-OCT) system (a), and sample path configu 
ration with a magnetic field generator (b). The magnetic field 
generator comprises a Solenoid, signal generator and current 
amplifier. A dual-channel Michelson interferometer was used 
to measure differential phase between light backscattered 
from a sample by applying a sinusoidal focused magnetic 
field excitation. Partially polarized light from an optical semi 
conductor amplifier (AFC Technologies, Rancho Cordova, 
Calif., central wavelength 1.31 um, FWHM=60 nm, opti 
cal coherence length 22 um) is polarized and coupled into 
fast and slow axes of a polarization-maintaining (PM) fiber in 
the input port. 
Optical path length change (Ap) in tissue can be calculated 
from the differential phase (A?p) and central wavelength of a 













The displacement Z(t) of tissue-laden nanoparticles driven 
by a time (t) varying magnetic flux density can be derived the 
analytic OCT fringe expression, 
(24) 
o 
Where I and Is are the back scattered signals from the 
reference and sample arms, respectively. f is the fringe car 
rier frequency, and Z(t) is the nanoparticles displacement. The 
OCT fringe signal can be expressed by the nanoparticles 
displacement equation (24). The two signals recorded from 
Channel 1 and 2 by the DP-OCT system can be used to 
measure nanoparticles displacement that represent relative 
Surface tissue displacement between two scanning beams. 
Finite element method (FEM) was used to design the mag 
netic field generator and evaluate space-time magnetic flux 
density. The magnetic field generator comprises a Solenoid 
(Ledex 6EC, Saia-Burgess Inc., Vernon Hills, Ill.), a function 
generator (HP 33120A, Hewlett Packard Inc., Palo Alto, 
Calif.), a current amplifier, and a power supply. FEM calcu 
lations (Maxwell SV. Ansoft Inc., Pittsburgh, Pa.) and 
Teslameter(R) (Magnetometer(R), AlphaI ab Inc., Salt Lake 
City, Utah) measurement indicated that the maximum mag 
netic flux density at a distance of 1.5 mm from the tip of the 
iron core was approximately 2 Tesla. The FEM simulation 
demonstrated that an ironcore positioned along the centerline 
of the Solenoid dramatically increased magnetic flux density 
at the target specimen. Magnetic field distributions from the 
FEM simulation showed the maximal and principal direction 
of the magnetic field strength was in the z-direction. The 
conical iron core provided focusing and Substantially 
increased the magnetic field strength. 
Differential phase OCT (DP-OCT) measurements were 
performed on isolated liver specimens taken from ApoE-/- 
mice administrated with different SPIO doses (1.0, 0.1 and 
0.01 mmol Fe/kg body weight) and saline control samples. 
FIG. 7 demonstrates measurements of transient optical path 
length change (Ap) in specimens at different SPIO doses (1.0, 
0.1 mmol Fe?kg body weight) and saline control samples, in 
response to application of a sinusoidal varying focused mag 
netic field. FIG. 13A shows a magnetic field input (f=2 Hz). 
peak-to-peak voltage (V.4) over a 1 second time period. 
The maximum magnetic field strength was 0.47 Tesla and 
maximal tissue displacement by optical path length change 
(Ap) was 2.273 nm in the 1.0 mmol Fe?kg iron-laden liver. 
Compared to high dose specimens, 0.1 mmol Fe?kg iron 
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laden liver showed a maximum optical path length change 
(Ap) of 127 nm with additive noise visible in recorded signals. 
Frequency response (4 Hz) of iron-laden livers (FIG. 7 (b). 
(c)) was exactly twice the modulation frequency (2 HZ) as 
noted earlier. No significant displacement of SPIO nanopar 
ticles was observed in either saline control liver specimens in 
the FIG. 13D or samples at the 0.01 mmol Fe?kg dose (not 
shown). 
SPIO nanoparticle movement in the iron laden livers (0.1, 
and 1.0 mmol Fe?kg) was used to observe quantitatively the 
relationship between optical path length change (Ap) versus 
different applied magnetic field strengths, as shown in FIG. 
14A. Input frequency used in this experiment was 2 Hz with 
amplitude from 2 to 8 V. FIG. 8 (b) shows magnetic flux 
density at the same voltages as in FIG. 14A. Magnitude of 
optical path length change (Ap) indicating movement of iron 
laden liver depended directly on the SPIO dose concentration, 
and strength of the external magnetic field. 
Optical path length change (Ap) at high frequency modu 
lation (over 100 Hz) was negligible due to limited frequency 
response of the structures surrounding SPIO nanoparticles. 
Generally, optical path length change (Ap) due to nanopar 
ticles movement in tissue increased with higher magnetic 
field strength. 
Optical path length change (Ap) in the iron-laden liver (0.1 
and 1.0 mmol Fe/kg) can be measured using a swept input 
frequency as shown in FIG. 15A. FIG. 15A shows the mag 
netic field input with a swept frequency from 1 to 10 Hz over 
a 2 second time-period. Magnitude of the optical path length 
change (Ap) was 2.318 nm in a high dose liver (1.0 mmol 
Fe/kg) and 177 nm in a low dose concentration (0.1 mmol 
Fe/kg), and magnetic field strength was 1.3 Tesla. The fre 
quency response of the force acting on the iron-laden liver is 
exactly twice the externally applied modulated frequency in 
FIG. 15B and FIG. 15C. No significant displacement was 
observed in the saline control liver shown in FIG. 9 (d) and 
0.01 mmol Fe/kg liver specimens. 
FIGS. 16A and 16B illustrates SPIO nanoparticle move 
ment measured by optical path length change (Ap) in a iron 
laden mouse liver to observe quantitatively the relationship 
between magnetic response in tissue versus different applied 
magnetic field strengths with Swept frequency ranging from 
1~10 Hz over a 2 second time-period. Magnitude of optical 
path length change (Ap) was larger when input Voltage was 
gradually increased from 2 to 10 V, during a frequency 
Sweep. Corresponding magnetic fieldstrength at these Volt 
ages was 1.24, 1.58, 1.71, 1.75 and 1.84 Tesla, respectively. 
For a given frequency Sweep, maximum optical path length 
change (Ap) for 0.1 and 1.0 mmol Fe?kg iron-laden liver 
specimens was 3,700 nm and 750 nm, respectively, at 10 V. 
and magnetic field of 1.84 Tesla. 
SPIO nanoparticles were identified in histological speci 
mens as blue granules from the Prussian blue stain of iron 
laden mouse livers. Compared to control liver specimens, iron 
laden specimens show significant iron accumulation evenly 
distributed in all observed areas. Although intracellular iron 
was also observed in control specimens, this natural iron was 
uniform and homogeneous rather than appearing in granular 
shapes as SPIO iron nanoparticles. Total SPIO iron area was 
5.45% of the histology image as calculated by Image-Pro 
PLUS 5.1 software (Mediacynernetics Inc., Silver Spring, 
Md.). 
Example 4 
Optical path length change (Ap) in iron-laden rabbit arter 
ies (0.1 Fe/kg) was measured in response to 2 Hz frequency 
sinusoidal input FIG. 17. FIG. 17A shows the magnetic field 
input with a constant frequency at 2 HZ over a 2.5 second 













(Ap) indicated a transient and steady state response. Transient 
response is evident in the exponentially decaying oscillation 
in the observed measured optical path length change at times 
between 0.5-1.0 seconds. Steady state response is evident in 
the uniform oscillation in the measured optical path length 
change at times between 1.25-3.0 seconds. Transient 
response indicates a high frequency (40 Hz-80 Hz) “ringing 
oscillation and a damping relaxation time of approximately 
0.3 seconds. The steady state frequency response of the force 
acting on the iron-laden rabbit artery was exactly twice the 
externally applied modulated frequency in FIG. 11 (b). 
Throughout this application, various publications are ref 
erenced. The disclosures of these publications in their entire 
ties are hereby incorporated by reference into this application 
in order to more fully describe the state of the art to which this 
invention pertains. 
While the invention has been described in connection with 
various embodiments, it will be understood that the invention 
is capable of further modifications. This application is 
intended to cover any variations, uses or adaptations of the 
invention following, in general, the principles of the inven 
tion, and including Such departures from the present disclo 
Sure as, within the known and customary practice within the 
art to which the invention pertains. 
What is claimed is: 
1. A method for detecting a lymphocyte, comprising: 
applying a first magnetic field strength to the lymphocyte, 
wherein the lymphocyte comprises a cellular membrane and 
a magnetically susceptible material; applying a second mag 
netic field strength to the lymphocyte, wherein the second 
magnetic field strength is different from the first magnetic 
field strength and interacts with the magnetically susceptible 
material to cause a change in the lymphocyte relative to 
interaction of the lymphocyte with the first magnetic field 
strength; and detecting the lymphocyte by detecting the 
change in the lymphocyte, wherein the change is detected 
using a phase sensitive frequency domain optical coherence 
tomographic imaging modality including a common path 
interferometer during the application of at least one of the first 
and second magnetic field strengths. 
2. The method of claim 1, wherein the change is selected 
from the group consisting of 
movement of the lymphocyte, movement of the magneti 
cally susceptible material, a change in the cellular mem 
brane tension level, and a change in the internal strain 
field of the lymphocyte. 
3. The method of claim 1, wherein the phase sensitive 
optical coherence tomographic imaging modality comprises 
using a probe for transmitting and receiving light energy to 
and from the lymphocyte. 
4. The method of claim 3, wherein the probe further com 
prises a magnetic source for applying at least one of the first 
and second magnetic field strengths to the lymphocyte. 
5. The method of claim 1, wherein at least one of the first 
and second magnetic field strengths is applied to the lympho 
cyte from a magnetic source located external to the probe. 
6. The method of claim 1, wherein the magnetically sus 
ceptible material is located within the lymphocyte. 
7. The method of claim 1, wherein the magnetically sus 
ceptible material is targeted to a location on the cellular 
membrane of the lymphocyte. 
8. The method of claim 1, wherein the magnetically sus 
ceptible material has a non-zero magnetic Susceptibility. 
9. The method of claim 8, wherein the magnetically sus 
ceptible material comprises a material selected from the 
group consisting of iron oxide, iron, cobalt, nickel, and chro 
mium. 
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10. The method of claim 1, wherein the magnetically sus 
ceptible material comprises a plurality of metallic nanopar 
ticles. 
11. The method of claim 10, wherein the nanoparticles are 
substantially spherical and have a diameter from about 0.1 
nanometers (nm) to about 1000.0 nm. 
12. The method of claim 10, wherein the nanoparticles are 
asymmetrical in shape. 
13. The method of claim 12, wherein the largest cross 
sectional dimension of the nanoparticles is from about 0.1 
nanometers (nm) to about 1000.0 nm in length. 
14. The method of claim 9, wherein the lymphocyte is 
detected in vivo and the magnetically susceptible material is 
administered to the subject. 
15. The method of claim 14, wherein the lymphocyte is a 
macrophage and wherein at least one nanoparticle is located 
within the macrophage. 
16. The method of claim 15, wherein the macrophage is 
located in an atherosclerotic plaque within the Subject. 
17. The method of claim 15, wherein the macrophage is 
located within the eye of the subject. 
18. The method of claim 14, wherein at least one of the 
nanoparticles is configured to localize to a target site within 
the subject. 
19. The method of claim 18, wherein the target site is a T 
lymphocyte. 
20. The method of claim 18, wherein the target site is B 
lymphocyte. 
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